

CURRICULUM VITAE

Professor Wen G. Jiang (姜文国), MB, BCh, MD, FSB, FRSM



**Metastasis & Angiogenesis Research Group
Institute of Cancer and Genetics
Cardiff University School of Medicine
Heath Park,
Cardiff, CF14 4XN
United Kingdom
Tel: 00 44 29 2074 2895
Fax: 00 44 29 2074 2896
e-mail: jiangw@cf.ac.uk
URL: <http://www.cf.ac.uk/medic>**

CURRICULUM VITAE

PERSONAL DETAILS:

NAME: Wen G JIANG (姜文国)
SEX : Male
MARRIAGE Married with two children
DATE OF BIRTH: 20 July 1962
NATIONALITY: British
HOME ADDRESS: 51 Ffordd Cwellyn, Sovereign Chase, Cyncoed
Cardiff CF23 5NB, U.K.
Tel: 44 29 2048 1069 / Email: l.jiang100@virgin.net
WORK ADDRESS: Metastasis and Angiogenesis Research Group
Institute of Cancer and Genetics (Section of Surgery)
Cardiff University School of Medicine
Heath Park, Cardiff CF14 4XN, U.K.
Tel: 44 29 2074 2895 /Fax: 44 29 2074 2895 /Mobile: 07875049374
e-mail: jiangw@cf.ac.uk / URL: <http://www.cf.ac.uk/medic>

CURRENT POSITION:

Professor in Surgery and Tumour Biology
Director for International and I&E, Institute of Cancer and Genetics
Academic Director for International Relations, Cardiff University

QUALIFICATIONS

M.B., BCh. (Hon) Beijing Medical University (now Peking University), 1984
M.D. University of Wales College of Medicine (now Cardiff University), 1995

EDUCATION AND POSTS HELD:

- Sept. 1979-----July 1984, Medical Student, Beijing Medical University, Beijing
- August 1984---Sept. 1987, Surgical Resident, Department of Surgery, First Teaching Hospital of Beijing Medical University, Beijing
- Oct. 1987-----Jan. 1989, Chief Surgical Resident, Department of Surgery, First Teaching Hospital of Beijing Medical University
- Mar. 1989-----July 1996, Research Fellow, University Department of Surgery, University of Wales College of Medicine, Heath Park, Cardiff CF4 4XN.
- Aug. 1996-----July 1997, Senior Fellow and Group Leader, University Department of Surgery, University of Wales College of Medicine (now Wales College of Medicine, Cardiff University), Cardiff, UK.
- Aug. 1997-----October 2003, Senior Lecturer and Group Leader, University Department of Surgery, Wales College of Medicine, Cardiff University (formerly known as University of Wales College of Medicine), Cardiff, UK.
- Sept. 2003 ---- Feb. 2004, Reader, Wales College of Medicine, Cardiff University (then UWCM). Head of Metastasis Research Group (UWCM).
- March 2004 ---, Professor of Surgery and Tumour Biology, Cardiff University. Head of Metastasis & Angiogenesis Research Group, Cardiff University School of Medicine (formerly known as University of Wales College of Medicine) (Group home page: <http://medweb.cf.ac.uk/mrg/>).
- April 2012 ---, Academic Director of International Operations, Cardiff University

PRIZES, AWARDS HONOURS,:

Professional Honours:

Fellow of the Chinese Life Science Society UK: 2009

Fellow of the Society of Biology (FSB): 2011

Fellow of Royal Society of Medicine (FRSM), 2012

Honorary Professor, Capital Medical University 2007

Honorary Professor, Peking University 2012

Honorary Professor, Inner Mongolia Medical University 2012

Other prizes, awards and honours: See a list in appendix-1

MEMBERSHIP OF LEARNT SOCIETIES:

- American Association for Cancer Research (AACR)
- British Association for Cancer Research (BACR)
- European Association for Cancer Research (EACR)
- Registered member of Human Genome Mapping Project (HGMP)

EDITORIAL WORK

- Co-editor in Chief of book series '*Cancer Metastasis, Biology and treatment*', Editors Jiang WG and R Ablin.
- Editor of '*Cancer Metastasis, molecular and cellular basis and clinical intervention*', with Professor RE Mansel, Kluwer Academic Publishers, 2000 (ISBN 0-7923-6395-7)
- Editor of '*Growth Factors and their receptors in cancer metastasis*', with Drs Nakamura and Matsumoto, Kluwer Academic Publishers, 2001 (ISBN 0-7923-7141-0)
- Co-editor, 'Breast Cancer Metastasis', Editors RE Mansel, Oystein Fodstad and WG Jiang, Spinger Publishers, 2007, ISBN: 978-1-4020-5866-0
- Guest Editor, 'HGF and cMET are potential targets in cancer treatment', for *Anti-cancer agents in Medicinal Chemistry*, 2010
- Managing Editor, 'Molecular and Cellular mechanisms of cancer metastasis and implication in cancer treatment', for *Frontiers in Bioscience*, 2010
- Issue Editor, 'HGF and cMET signalling in disease and therapies', 2010
- Section editor, 'Breast Cancer', for *Current Opinions in Oncology*, from 2007-2010
- Issue Editor '*HGF and signalling in clinical medicine*', for *Current Signal Transduction and Therapies*, 2010-2011
- Managing Editor, 'Bone Metastasis, Molecular, Cellular and Clinical Prospectives', for *Frontiers in Bioscience*, 2013

- Member of the editorial board of the *International Journal of Molecular Medicine*, from 1999
- Editorial Board '*International Seminars of Surgical Oncology*', from 2006
- Advisory Board Member, '*Advances in Therapy*', from 2008
- Editorial Board Member, '*Current Oncology*', from 2008
- Editorial Board Member, '*Journal of Surgical Oncology*', from 2008
- Editorial Board Member, '*Current Signal Transduction Therapy*', from 2009

- Editorial Board Member, ‘*Experimental and Therapeutic Medicine*’, from 2009
- Senior Editor, ‘*Journal of Chinese Clinical Medicine*’. From 2009
- Editorial Board Member, ‘*World Journal of Clinical Oncology*’. From 2010
- Editorial Board Member, ‘*International Wound Journal*’. From 2009
- Editorial Board Member, ‘*World Journal of Oncology*’. From 2010
- Editorial Board Member, ‘*Gene Review Letters*’, from 2009
- Editorial Board Member, ‘*Chinese Journal of Cancer Research*’. From 2010
- Editorial Board Member, ‘*Current Cancer Therapy Reviews*’. From 2010
- Editorial Board Member, ‘*International Journal of Oncology*’, from 2011
- Editorial Board Member, ‘*Translational Medicine: Current Research*’, from 2011
- Editorial Board Member, ‘*The Scientific World Journal*’, from 2011
- Editorial Board Member, ‘*Translational Gastrointestinal Cancer*’, from 2011
- Editorial Board Member, ‘*Biomedical Reports*’, from 2012

OTHER NON-ACADEMIC ACTIVITIES - INTERNATIONAL

- Developing academic links between Cardiff University-Capital Medical University from 2006, which has led to form MOU between Cardiff and CMU, Award of International Advisorship and Consultantship to Cardiff official (Cardiff's V-C and MedDean). This has led to creation of Cardiff University-Capital Medical University Joint Centre for Biomedical Research, launched in Beijing May 2012
- Developing academic links between Cardiff University-Peking University from 1996, which has led to form MOU between Cardiff and Peking in 2007 and 2012. This has led to creation of Cardiff University-Peking University Cancer Joint Institute, launched at a high profile event in Beijing in May 2012
- Development of academic links with Chongqing Cancer Hospital, in support of Wales-Chongqing link.
- Creation of China Medical Scholarship at Cardiff University. Created in 2007, The Scholarship has attracted investment from overseas.
 - More than 30 Chinese medical scholars have come to Cardiff, supported by this scholarship
 - To high profile events (2010 and 2012) took place in Beijing's the Great Hall of the People, to award the certificates to the scholars, at which top Chinese leaders attended the events.
 - The scholarship has won Cardiff University the prestigious Times Higher Education 'International Collaboration of the Year of UK Universities' in November 2011, the only winner of all the University in Wales

OTHER NON-ACADEMIC ACTIVITIES - INNOVATION AND COMMERCIAL

- PATENTS

Cancer related technologies

- Patent inventor of ‘a new anti-angiogenesis reagent’, filed 2001
- Patent inventor ‘Prognostic kit in breast cancer’, filed 2004
- Patent inventor ‘HAIs in cancer therapy’, filed 2004
- Patent inventor ‘BMP-9 and -10 as new anticancer therapies’, filed 2006
- Patent inventor ‘New therapies for prostate cancer, MAT2’, filed 2006

- Patent inventor ‘Ciglitizone and GLA in cancer treatment’, filed 1997

Wound healing related technologies

- United Kingdom 0916124.1 15/09/09 Method and Kit for the Classification and Prognosis of Wounds
- United Kingdom 1021182.9 14/12/10 Method and Kit for the Classification and Prognosis of Wounds
- United Kingdom 1003652.3 05/03/10 Molecular target for Healing or Treating Wounds (n-WASP)
- United Kingdom 1103898.1 08/03/11 Molecular Targets for Wound Healing
- United Kingdom 1103962.5 09/03/11 Molecular Targets for Wound Healing
- United Kingdom 1104082.1 10/03/11 Molecular Targets for Wound Healing

- SPINOFF COMPANIES

The above patents have lead to two/three spin off companies in Cardiff

- Cardiff Biologicals: 2007 (subsequently acquired by Morvus Biotechnologies)
- Wound Genetics 2012 (formed May 2012 by Fusion)
- Wound Therapeutics (to form in the course of 2012)

RESEARCH PROFILE

Area of research expertise:

Cancer Metastasis, angiogenesis, breast cancer, prostate cancer, wound healing/tissue repair

Research Grants received: Appendix-2

Publications:

Published books: appendix-3

Full papers: appendix-4

SCI Researcherid Number: B-1293-2010

SCI citation H-index: 49 (June 2012)

SCI Citation detailed report: June 2012 (method: Jiang W*, Cardiff)

SCI publications: 572

Total citation: 7530

H-index: 49

Accumulated Citation Index (Feb 2012): 874


[<< Back to previous page](#)

Citation Report Author=(jiang w* or jiang g*) AND Address=(cardiff)

Timespan=All Years.

This report reflects citations to source items indexed within All Databases.


Published Items in Each Year



The latest 20 years are displayed.

[View a graph with all years.](#)

Citations in Each Year



Results found: 572

Sum of the Times Cited [?]: 7530

Citing Articles[?]: 5192

h-index [?]: 49

Appendix-1: Prizes, Awards and Honours

2012

- 'Cover Legend', International Journal of Oncology, 2012, 40(April issues)
- Honorary Professor, Peking University
- Honorary Professor, Inner Mongolia Medical University

2011

- International Collaboration Award of the Year of UK Universities, Times Higher Education. Nov 2011
- 'Pinnacle of Achievement Award', by American Biographical Institute

2010

- 'Man of the Year in Medicine and Healthcare', by American Biographical Institute

2009

- December 2009, AACR Investigator Award, to Dr Tracey A Martin, for a study on 'Expression of stem cell markers in human breast cancer'. Martin TA, Mansel RE, **Jiang WG**. Received in December 2009, San Antonio, Texas, US
- October 2009, Best Presentation Award by the Welsh Urological Society, to Dr Mohammed Mozaam, for a study on 'WAVEs in the aggressiveness of Prostate cancer cells'. Moazzam M, Ye L, Kynaston H, **Jiang WG**. Received in October 2009, Wales, UK

2007

- Honorary Professor, Capital Medical University

2006

- February 2006, ASCO Foundation Investigator's Merit Award, to Dr Jo Lewis-Russell, for a study on 'Growth differentiation factor 9 inhibits the proliferation of human prostate cancer cells'. Lewis-Russell J, Mason MD, Kynaston H and **WG. Jiang**. Received in February 2005, Orlando, Florida, US
- February 2006, ASCO Foundation Investigator's Merit Award, to Dr Azad Howizy, for a study on 'Over-expression of WISP-2 reduces HGF induced invasion of prostate cancer cells' Howizy A, G. Davies, Kynaston H and **WG. Jiang**. Received in February 2006, San Francisco, California, US
- February 2005, ASCO Foundation Investigator's Merit Award, to Dr Gaynor Davies, for a study on 'EPLIN acts as an inhibitor of cell-matrix adhesion in prostate cancer cells', G. Davies, Kynaston H, Mason MD and **WG. Jiang**. Received in February 2006, San Francisco, California, US
- February 2005, ASCO Foundation Investigator's Merit Award, to Dr Gaynor Davies, for a study on 'Genetically manipulation of Expression of BMP7 and its impact on the motility and invasion of prostate cancer cells', Ye L, Russell-Lewis J, Davies G, Mason MD, Kynaston H, **WG. Jiang**. Received in February 2006, San Francisco, California, US
- September 2006, British Prostate Group, Best presentation award to Mr Andrew Sanders 'A.J. Sanders, C. Parr, G. Davies, M.D. Mason, W.G. Jiang. Suppression of HAI-1 expression increases the aggressive nature of prostate cancer cells '.
- November 2006, Welsh Urological Society, HUU Willima Award to Dr Ninnard Anware for a study on 'NS Awsare, *TA Martin, HG Kynaston, PN Matthews and ***WG Jiang**. Overexpression of claudin-11 alters the malignant phenotype of invasive bladder cancer cells, with little effect on Tight Junction epithelial

2005

- February 2005, ASCO Foundation Investigator's Merit Award, to Dr Gaynor Davies, for a study on 'VHL expression on the invasiveness of prostate cancer cells *in vitro*: clinical implications in human prostate cancer, G. Davies, MK Zia, GM. Harrison, G. Watkins, MD. Mason, H. Kynaston and **WG. Jiang**. Received in February 2005, Orlando, Florida, US
- February 2005, ASCO Foundation Investigator's Merit Award, to Dr Azad Howizy, for a study on Hawiz A, Davies G, Mason MD, Kynaston H, **Jiang WG**. The role of WISPs in human prostate cancer. Presented to Prostate Cancer Symposium, American Society of Clinical Oncology, February 2005, Orlando, Florida, US

2004

- December 2004, 'San Antonio Breast Cancer Program Scholar Award' to Mrs Jane Lane for a study 'The role of Rock-1 and Rock-2 in the aggressiveness of human breast cancer cells, Jane Lane, RE Mansel and **WG Jiang**'.

2003

- December 2003, 'San Antonio Breast Cancer Program Scholar Award' to Dr Mahir Al-Rawi for a study 'Interleukin-7 is lymphangiogenic, role of VEGF-D, M Al-Rawi, RE Mansel and **WG Jiang**'.
- May 2003, 'The Best Research Team Award' from Breast Cancer Research Campaign, received at the House of Lord, London.

2002

- December 2002, San Antonio Breast Cancer Program Scholar Award to Dr T A Martin for a study 'Aberrant expression of tight junction molecules are associated with prognosis of breast cancer, TA Martin, RE Mansel and **WG Jiang**'.
- April 2002, American Association of Cancer Research Scholar-in-Trainig Award to Dr G Davies, who presented the study from the research 'NK4 and the prostate cancer growth in a mice model, Davies G, Mason MD, **Jiang WG**'

1998

- March 1998, Young Investigator's award to S Hiscox for a study 'HGF/SF regulates the phosphorylation of β -catenin and cell-cell adhesion in cancer cells, Hiscox S and **Jiang WG**', by the American Association for Cancer Research.
- June/July 1998 British Council, International travelling fellowship

1993

- May 1993, Best presentation prize from European Congress of Hepato-Pancreato-Biliary Association for a paper entitled "Imbalance between TNF α and TNF inhibitor in patients with Obstructive jaundice" by MCA Puntis and **WG Jiang**.

- 2011 Featured Legend by International Journal of Oncology,
- 2011 International Profiles of Accomplished Leaders in Medicine, The American Biographical Institute
- 2010 Man of the Year in Medicine and Healthcare, The American Biographical Institute
- Listed in Great Minds of 21 Century, 2010, The American Biographical Institute, 2010
- Listed in Who's Who in the World (2003-2012)
- Listed in Who's Who in Science and Engineering (2005-2012)
- Listed in Dictionary of International Biography, 23rd edition (2004)
- Listed Who's Who in Medicine and Health Care (2002-2012)
- Listed in the Marquis Who's Who Professionals (edition 2000-2001)
- Listed in the Marquis Who's Who in America (edition 2008, 2009)
- Listed in 'Asia Admirable Achievers', Volume III, 2009
- Listed in Afro-Asian Who's Who 2006-
- Listed in Asia-Pacific Who's Who 2007-
- Listed in Selected Personalities in Asia, 2010
- Listed in the 'The Powerlist of Wales', 2001 and 2002
- May 1997. British Council – Argentina collaboration award (with Dr AR Eynard and Professor Mansel), for a collaboration and visit to the University of Cordoba School of Cell Biology, for a lecture
- December 1997. The British Council visiting fellow. To visit Osaka University Medical School, to explore the bilateral collaboration and deliver a lecture

- Member of the Scientific Committee, Breast Cancer Hope Foundation

- Board Member of Academic Committee, Oncology, Capital Medical University

- Fellow, The Academy of Life Sciences for Chinese in the UK

- External PhD programme assessing panel, COMSATS Institute of Information Technology
-
- Board member, Cancer Research UK (CR-UK), China Fellowship Programme

- Member of Focus Group, San Antonio Breast Cancer Focus Group, Dec 2008

- Creation of China Medical Scholarship in Cardiff University, 2008

- Committee member, Beijing International Cancer Forum, October 2009

- Scientific Committee, The Oriental Cardiovascular and Angiogenesis Conference, Shanghai, 2010

- Scientific Committee, Capital International Cancer Conference 2010, Beijing, 2010

- Session Chair (5-3), 4th World Cancer Congress (BIT), Dalian, China 22-25 May 2011
- Session Chair (5-7), 3rd World DNA Day, Xi'an, China 25-28 April 2012

- Member of Executive Board, International Society of Collateral Diseases, from 2011
- Visiting Professor, Inner Mongolia Medical University, from 2012
- Honorary Professor, Peking University 2012
- Vice-President elect, World Association of TCM, Society of Collateral Diseases, from June 2012

Appendix-2: Grants received - not listed

Appendix-3. Publications: Books

- **'Cancer Metastasis, molecular and cellular basis and clinical intervention'**, Co-Edited with Professor RE Mansel, Kluwer Academic Publishers, 2000 (ISBN 0-7923-6395-7)
- **'Growth Factors and their receptors in cancer metastasis'**, Co-Edited with Drs Nakamura and Matsumoto, Kluwer Academic Publishers, 2001 (ISBN 0-7923-7141-0)
- **'Breast Cancer Metastasis'**, Editors RE Mansel, Oystein Fodstad and WG Jiang, Springer Publishers, 2007, ISBN: 978-1-4020-5866-0
- **'Electric Cell-Substrate Sensing in the investigation of cancer and cancer metastasis'**. WG Jiang. Springer Publishers, 2012. ISBN 978-94-007-4926-9
(<http://www.springer.com/biomed/cancer/book/978-94-007-4926-9>)
- **'Tight junctions in cancer metastasis'**. TA Martin and WG Jiang. Springer Publishers, March 2013

Appendix-4 Publications: full pappers

2012

1. Escudero-Esparza A, Martin TA, **Jiang WG** . Claudin-5 is involved in breast cancer cell motility through N-WASP and ROCK signalling pathway. *Molecular and Cellular Biochemistry*, 2012, 362(1-2), 71-85
2. Li J, Ye L, Kynaston HG, **Jiang WG**. The role of RGM-B (Dragon in the aggressiveness of prostate cancer cells. *International Journal of Oncology.*, 2012, 40(2), 544-550
3. Du P, Ye L, Li H, Yang Y, **Jiang WG**. Growth differentiation factor-9 (GDF-9) act as a putative tumour suppressor in Human Urothelial Cancer of Bladder. *International Journal of Molecular Medicine*, 2012, 29(3), 428-434
4. Bosanquet DC, Ye L, Harding KG, **Jiang WG**. The role of HuR in keratinocyte migration and wound healing. *Molecular Medicine Reports*, 2012, 5(2), 529-534
5. **Jiang WG**, Sander AJ, Ruge F, Harding KG. Influence of Interleukin-8 (IL-8) and IL-8 receptors on the migration of human keratinocytes, the role of PLC γ and potential clinical implications. *Experimental and Therapeutic Medicine*, 2012, 3(2), 231-236
6. Wazir U, **Jiang WG**, Sharma AK, Mokbel K. The mRNA expression of DAP3 is human breast cancer: correlation with clinicopathological paramters. *Anticancer Research*, 2012, 32, (2), 671-674
7. Martin TA, Tomms AM, Davies LM, Cheng S, **Jiang WG**. The clinical and biological implications of N-WASP expression in human colorectal cancer. *Translational Gastrointestinal Cancer*, 2012, 1(1), 10-20
8. Li J, Kynaston HG, Ye L, **Jiang WG**. Repulsive guidance molecules (RGMs) and their implication in cancer as co-receptor of BMPs . *Current Signal Transduction Therapy*, 2012, 7(2), 149-160
9. Liu YN, Chen JF, Yang Y, Zhang LJ, **Jiang WG**. The molecular impact of Bone Morphogenetic Protein-7, BMP7, on lung cancer cells and the clinical significance. *International Journal of Molecular Medicine*, 2012, 29(6), 1016-1024
10. Salhab M, Patani N, **Jiang WG**, Mokbel K. High TIMM17A Expression is Associated with Adverse Pathological & Clinical Outcomes in Human Breast Cancer. *Breast Cancer*, 2012, 19(2), 153-160
11. Liu Y, Sanders AJ, Zhang L, **Jiang WG**. EPLIN- α Expression in Human Oesophageal Cancer and its Impact on Cellular Aggressiveness and Clinical Outcome. *Anticancer Res.* 2012 Apr;32(4):1283-9
12. Escudero-Esparza A, Martin TA, **Jiang WG**, Claudin-5 participates in the regulation of endothelial cell motility. *Journal of Experimental and Clinical Cancer Research*, 2012, 31(1), 43
13. Li J, Ye L, **Jiang WG**. Repulsive guidance molecule B (RGMB) plays negative roles in breast cancer by coordinating BMP signaling. *Journal of Cellular Biochemistry*, 2012, 113(7), 2523-2531
14. Li X, Martin TA, **Jiang WG**. COM-1/p8 Acts as a Tumour Growth Enhancer in Colorectal Cancer Cell Lines. *Anticancer Res.* 2012 Apr;32(4):1229-37
15. Du P, Ye L, Li H, Yang Y, Ruge F, **Jiang WG**. Metastasis Suppressor-1, MTSS1, act as a putative tumour suppressor in human kidney cancer. *Journal of Experimental and Therapeutic Oncology*, 2012 in press
16. Liu CL, Tam JCW, Sanders AJ, Jiang DG, Ko CH, Fung KP, Leung PC, Harding KG, **Jiang WG** and Lau CBS. Electric cell-substrate impedance sensing as a screening tool for wound healing agents. *Cancer Metastasis Biology and Treatment (ECIS in cancer metastasis)*, 2012, in press
17. Bosanquet D, Harding KG, **Jiang WG**. Electric cell-substrate impedance sensing , cellular adhesion and migration in keratinocytes. *Cancer Metastasis Biology and Treatment (ECIS in cancer metastasis)*, 2012, in press
18. Sanders AJ, Saravolac VM, Mason MD and **Jiang WG**. Electric cell-substrate impedance sensing , as a tool in the study of metastasis suppressor genes: EPLIN. *Cancer Metastasis Biology and Treatment (ECIS in cancer metastasis)*, 2012, in press
19. Martin TA and **Jiang WG**. Tight Junctions in Cancer Metastasis and their investigation using ECIS (ELECTRIC Cell-substrate Impedance Sensing). *Cancer Metastasis Biology and Treatment (ECIS in cancer metastasis)*, 2012, in press
20. Lane J and **Jiang WG**. Epithelial-mesenchymal transition and the use of ECIS. *Cancer Metastasis Biology and Treatment (ECIS in cancer metastasis)*, 2012, in press
21. **Jiang WG**. Molecular biology and medical and surgical practice. Surgery, CMU Press, 2012
22. Chen Xie, Xiao Hua Jiang, Yin Rui Diao, Ting Ting Sun, Ting Jie Zhang, Kin Lam Fok, Xiao Dong, Lai Ling Tsang, Mei Kuen Yu , Xiaohu Zhang, Yiu Hua Chung, **Wen Guo Jiang**, Hsiao Chang Chan. CFTR as tumor suppressor and prognostic indicator. *Oncogene*, 2012
23. Ye L, Sun PH, Martin TA, Sanders AJ, Mason MD, **Jiang WG**. Psoriasis (S100A7) is a potent regulator of survival and invasion of prostate cancer cells. *Urologic Oncology*, 2012 in press

24. Martin TA, Ye L, Sanders AJ, Lane J, **Jiang WG**. Cancer Invasion and metastasis, a molecular and cellular perspective. *Cancer Invasion and Metastasis, a molecular and clinical perspective*, 2012
25. Ye L, Ji K, Ji JF, Hargest R, **Jiang WG**. Application of Electric Cell-Substrate Impedance Sensing in evaluation of traditional medicine on the cellular functions of gastric and colorectal cancer cells *Cancer Metastasis Biology and Treatment (ECIS in cancer metastasis)*, 2012, in press
26. **Jiang WG**, Ye L, Ren H, Anna , Topley N, Mason MD. Tumour-endothelial and tumour-mesothelial interactions investigated by ECIS. *Cancer Metastasis Biology and Treatment (ECIS in cancer metastasis)*, 2012, in press
27. Ye L, Ji K, Frewer N, **Jiang WG**. Cellular impact of *Yangzheng Xiaoji* on the adhesion and cellular migration of human cancer cells and the potential underlying signalling pathways. *Anticancer Research*, 2012, 32(7), 2537-2543
28. Baig RM, Sanders AJ, Kayani MA, **Jiang WG**. Association of Differentiation-related gene-1 (DRG1) with breast cancer survival and in vitro impact of DRG-1 suppression. *Cancers*, 2012 in press
29. Wazir U, **Jiang WG**, Sharma AK, Mokbel K. The mRNA Expression of *DAP1* in Human Breast Cancer: Correlation with Clinicopathological Parameters. *Cancer Genomics and Proteomics*, 2012
30. **Jiang WG**. Cancer Metastasis, high time to refocus cancer research. *Public Serview Review, UK Science and Technology* 2012, 6, p--
31. Ji K, Ye J, Toms AM, Hargest R, Martin TA, Ruge F, Ji JF, **Jiang WG**. Signal-induced proliferation-associated gene 1 (*SIPAI*), a RapGTPase-activating protein is increased in colorectal cancer and has diverse effects on functions of colorectal cancer cells. *Cancer Genomics and Proteomics*, 2012 in press
32. **Jiang WG**, Ye L, Frewer N, Sanders AJ, Mason MD. Angiogenesis inhibitory effects of *Yangzheng Xiaoji*, the role of focal adhesion kinase, FAK pathway. *International Journal of Oncology*, 2012 in press
33. Webb SL, Sanders AJ, Mason MD, **Jiang WG**. The influence of matriptase-2 on prostate cancer in vitro: a possible role for β -catenin. *Oncology Reports*, 2012 in press
34. Yang XM, Martin TA, **Jiang WG**. Biological Influence of Brain Derived Neurotrophic Factor (BDNF) on Breast Cancer Cells. *International Journal of Oncology*, 2012, in press
35. Bosanquet DC, Harding KG, Ruge F, Sanders AJ, **Jiang WG**. Expression of IL-24 and IL-24 receptors in human wound tissues and the biological implications of IL-24 on keratinocytes. *Wound Repair and Regeneration*, 2012,
36. Martin TA and **Jiang WG**. Tight junctions in the progression of breast cancer. *Cancer Metastasis Biology and Treatment (Tight Junctions and cancer metastasis)*, 2012, in press
37. Martin TA, Haynes M, Answare N, Brown G and **Jiang WG**. Tight junctions in human urinary bladder cancer. *Cancer Metastasis Biology and Treatment (Tight Junctions and cancer metastasis)*, 2012, in press

2011

38. **Jiang WG** and Ablin RJ. Cancer metastasis, challenges, progress and the opportunities. *Frontiers in Bioscience*, 2011, 16, 391-394
39. **Jiang WG** and Sanders AJ. Hepatocyte growth factor is a potential lymphangiogenesis factor. *Current Signal Trasduction Therapy*, 2011, 6(2), 168-172
40. Al-Rawi MA and **Jiang WG**. Lymphangiogenesis and cancer metastasis. *Frontiers in Bioscience*, 2011 , 16, 723-739
41. Webb S, Sanders AJ, Mason MD, **Jiang WG**. Type II tranmembrane serine proteinase (TTSP) deregulation in Cancer. *Frontiers in Bioscience*, 2011, 16, 539-552
42. Cheng S, Martin TA, Teng X, **Jiang WG**. Putative breast tumour suppressor TACC-2 supresses the aggressiveness of breast cancer cells through a PLC-gamma pathway. *Current Signal Transduction and Therapies*, 2011, 6(1), 55-64
43. Lane J, Martin TA, **Jiang WG**. HGF and RhoGTPases in cancer cell motility. *Current Signal Transduction and Therapies*, 2011, 6(2), 173-179
44. Martin TA and **Jiang WG**. Claudin-16/paracellin-1, cloning, expression and its role in tight junctions in cancer and endothelial cells. *Methods in Molecular Biology*, 2011 , 762 (28), 383-407 (DOI 10.1007/978-1-61779-185-7_28)
45. Martin TA, Escudero-Esparza A, **Jiang WG**. Tight junctions in cancer metastasis. *Frontiers in Bioscience*, 2011, 16, 898-936
46. Ye L and **Jiang WG**. Bone morphogenetic proteins in bone metastasis. *Frontiers in Bioscience*, 2011, 16, 865-897
47. **Jiang WG** and Matsumoto K. Hepatocyte growth factor and its receptor and the therapeutic implications. *Current Signal Transduction and Therapies*, 2011, 6(2), 141-142

48. Martin TA, Mason MD, **Jiang WG**. Hepatocyte growth factor signalling in cancer metastasis. *Current Signal Transduction and Therapies*, 2011, 6(2), 180-190s
49. Escudero-Esparza A, **Jiang WG**, Martin TA. The claudin family and its role in cancer and metastasis. *Frontiers in Bioscience*, 2011, 16, 1069-1083
50. Yu HF, Zhang YX, Ye L, **Jiang WG**. The FERM family proteins in cancer invasion and metastasis. *Frontiers in Bioscience*, 2011, 16, 1536-1550
51. Xie F, Martin TA, Zhang LJ, **Jiang WG**. Metastasis suppressor-1, MTSS1, a multifunctional protein and its role in cancer invasion and metastasis. *Frontiers in Bioscience (Schol Ed)*, 2011, 3, 621-631
52. Yuan Z, Sanders AJ, Ye L, Wang Y, Mansel RE, **Jiang WG**. Prognostic value of the human (Hu) antigen R (HuR) in human breast cancer: high level predicts a favourable prognosis. *Anticancer Research*, 2011, 31(1), 303-310
53. Mustafa N, Martin TA, **Jiang WG**. Metastasis tumour suppressor-1, MTSS-1 and the aggressiveness of prostate cancer cells. *Experimental and Therapeutic Medicine*, 2011, 2, 157-162
54. Bokobza SM, Ye L, Kynaston HG, **Jiang WG**. GDF9a induces Epithelial-Mesenchymal transition (EMT) in prostate cancer. *Molecular and Cellular Biochemistry*, 2011, 349, 33-40
55. Martin TA, Harrison GM, Mason MD, **Jiang WG**. The Hepatitis A virus Cellular Receptor, HAVcR-1, reduces the integrity of human endothelial tight junctions. *Anticancer Research*, 2011, 31, 467-473
56. Ge ZC, Sanders AJ, Ye L, Wang Y, **Jiang WG**. Expression of Death Decoy receptor-3(DcR3) in Human Breast Cancer and its Functional Effects of Breast Cancer Cells in Vitro. *Journal of Experimental Therapeutics and Oncology*, 2011, 9, 109-118
57. Asware N, Martin TA, Matthews N, **Jiang WG**. Claudin-11 decreases the invasiveness of bladder cancer cells. *Oncology Reports*, 2011, 25(6), 1503-1509
58. Ge ZC, Sanders AJ, Ye L, **Jiang WG**. Aberrant expression and function of Death receptor-3 (DR3) and Death decoy receptor-3 (DcR3) in human cancer. *Experimental and Therapeutic Medicine*, 2011, 2 (2), 167-172
59. Yuan Z, Sanders AJ, Ye L, Wang Y, **Jiang WG**. Knockdown of Human (Hu) antigen R (HuR) reduces the growth and invasion of breast cancer cells *in vitro* and affects expression of cyclin D1 and MMP-9. *Oncology Reports*, 2011, 26, 237-245
60. Minhas U, Martin TA, Ruge F, Harding KG, **Jiang WG**. Pattern of expression of the CCN family members, Cyr61, CTGF and Nov in human acute and chronic wounds. *Experimental and Therapeutic Medicine*, 2011, 2, 641-645
61. Cai J, Wu L, Qi X, Shaw L, LiCalzi S, Caballero S, **Jiang WG**, Viores S, Antonetti D, Ahmed A, Grant MB and Michael E Boulton. Placenta growth factor antagonizes VEGF-induced vascular permeability by stabilizing adherens junctions in endothelial cells. *PloS One*, 2011, 6(3), e18076 (1-16)
62. Li J, Ye L, Mansel RE, **Jiang WG**. RGMs (repulsive guidance molecules) and the potential prognostic value in cancer. *Anticancer Research*, 2011, 31 (5), 1703-1711
63. Ablin RJ, Kynaston HG, Mason MD, **Jiang WG**. Prostate transglutaminase (TGase-4) antagonises the anti-tumour action of MDA7/IL-24 in prostate cancer. *Journal of Translational Medicine*, 2011, 9(1), 49
64. Ablin RJ and **Jiang WG**. The role of transglutaminases in the pathophysiology of the prostate. *Current Oncology*, 2011, 18(5), 241-242
65. **Jiang WG** and Ablin RJ. Prostate Transglutaminase-4, a unique transglutaminase and its role in prostate cancer. *Biomarkers in Medicine*, 2011, 5(3), 285-291
66. Sanders AJ, Jiang DG, **Jiang WG**, Harding KG, Patel GK. Activated leucocyte cell adhesion molecule (ALCAM) impacts on clinical wound healing and inhibitors HaCaT migration. *International Wound Journal*, 2011, 8(5), 500-507
67. Xie F, Ye L, Chen J, Yang Y, Zhang LJ, **Jiang WG**. The impact of metastasis suppressor-1 on oesophageal squamous cell carcinoma and its clinical significance. *Journal of Translational Medicine*, 2011, 9:95
68. Sanders AJ, Martin TA, Ye L, Mason MD, **Jiang WG**. EPLIN is a negative regulator of prostate cancer growth. *Journal of Urology*, 2011, 186(5), 1703-1711
69. Chen J, Xie F, Zhang L, **Jiang WG**. iAPP is over-expressed in human non-small cell lung cancer and regulates the proliferation of lung cancer cells through a p53 associated pathway. *Archiv Euromedica*, 2011, 1/2, 37-41
70. Patani N, **Jiang WG**, Mokbel K. Brain-Derived Neurotrophic Factor Expression Predicts Adverse Pathological & Clinical Outcomes in Human Breast Cancer. *Cancer Cell International*, 2011, 11: 23
71. Du P, Ye L, Ruge F, Yang Y, **Jiang WG**. Metastasis Suppressor-1, MTSS1, act as a putative tumour suppressor in bladder cancer. *Anticancer Research*, 2011, 31(10), 3205-3212,

72. Patani N, **Jiang WG**, Mokbel K. Histone modifier gene expression profiles are associated with pathological and clinical outcomes in human breast cancer. *Anticancer Research*, 2011, 31 (12), 4115-4225
73. Ruan Q, Han S, **Jiang WG**, Boulton ME, Chen ZJ, Law BK, Cai J. α B-crystallin, a downstream effector of the unfolded protein response, confers anti-VEGF therapy resistance to breast cancer through the maintenance of intracrine VEGF signaling in tumor endothelial cells. *Molecular Cancer Research*, 2011, 9(12), 1632-1643

2010

74. Ablin RJ and **Jiang WG**. All fats are not bad, smart lessons to be learned. *Journal of Urology*, 2010, 183, 13-14
75. Fernando H, Martin TA, Watkins G, Kynaston H, Mansel RE, **Jiang WG**. Expression of the ERM family members (ezrin, radixin, and moesin) in human breast cancer. *Experimental and Therapeutic Medicine*, 2010,1, 153-160
76. Escudero-Esparza A, Martin TA, Douglas-Jones A, Mansel RE, **Jiang WG**. PGF isoforms, PLGF-1 and PGF-2 and the PGF receptor, neuropilin, in human breast cancer and the prognostic significance. *Oncology Reports*, 2010, 23 (2), 537-544
77. Zhang N, Sanders AJ, Ye L, Kynaston HG, **Jiang WG**. Expression of Vascular endothelial growth inhibitor (VEGI) in human urothelial cancer of the bladder and its impacts on the adhesion and migration of bladder cancer cells *in vitro*. *Anticancer Research*, 2010, 30: 87-95
78. Parr C, Sander AJ, **Jiang WG**. Hepatocyte growth factor activation inhibitors – therapeutic potential in cancer. *Anti-Cancer Agents in Medicinal Chemistry*, 2010, 10(1), 47-57
79. Martin TA and **Jiang WG**. Editorial: HGF and cMET, targets in cancer therapies. *Anti-Cancer Agents in Medicinal Chemistry*, 2010, 10 (1). 2-6
80. Sanders AJ, Webb SL, Parr C, Mason MD, **Jiang WG**. The Type II Transmembrane Serine Protease, Matriptase-2: Possible links to cancer? *Anti-Cancer Agents in Medicinal Chemistry*, 2010, 10 (1), 64-69
81. Martin TA and **Jiang WG**. Hepatocyte Growth factor and its receptor signalling complex as targets in cancer therapy. *Anti-Cancer Agents in Medicinal Chemistry*, 2010, 10(1), 1-1
82. Sanders AJ, Guo X, Webb SL, Mason MD, **Jiang WG**. IL-17B and IL-17B receptor in regulation of angiogenesis. *Journal of Oncology*, 2010, 2010, 817375
83. Fernando H, Sanders AJ, Kynaston H, **Jiang WG** WAVE3 is associated with invasiveness but not cell proliferation in prostate cancer cells. *Urologic Oncology*, 2010, 28(3), 320-327
84. Sasi W, **Jiang WG**, Sharma A, Mokbel K. Higher expression levels of SOCS1,3,4,7 are associated with earlier tumour stage and better clinical outcome in human breast cancer. *BMC Cancer*, 2010, 30(1), 178
85. Yuan Z, Ye L, Sanders AJ, **Jiang WG**. HuR, and its role in the development and progression of breast cancer. *Histology and Histopathology*, 2010, 25 (10), 1331-1340
86. Davies ML, Parr C, Sanders AJ, Fodstad O, **Jiang WG**. The transcript expression and protein distribution pattern in human colorectal carcinoma reveal a pivotal role of Com-1/p8 as a tumour suppressor. *Cancer Genomics and Proteomics*, 2010, 7(2), 75-80
87. Davies SR, Davies ML, Sanders AJ, Parr C, Torkington J, **Jiang WG**. Differential expression of the CCN family member WISP-1, WISP-2 and WISP-3 in human colorectal cancer and the prognostic implications. *International Journal of Oncology*, 2010, 36(5), 1129-1136
88. Chen JF, Ye L, Xie F, Yang Y, Zhang LJ, **Jiang WG**. Expression of bone morphogenetic protein (BMP)-7 in lung cancer and the biological impact of BMP-7 on lung cancer cells. *Anticancer Research*, 2010,30, 1113-1120
89. Cai W, Ye L, Sun J, Mansel RE, **Jiang WG**. Expression of MLN64 influences cellular matrix adhesion of breast cancer cells, the role for focal adhesion kinase (FAK). *International Journal of Molecular Medicine*, 2010, 25, 573-580
90. Cheng S, Douglas-Jones A, Yang X, Mansel RE, **Jiang WG**. Transforming Acidic Coiled-coil-containing Protein 2 (TACC2) in human breast cancer, expression pattern and clinical/prognostic relevance. *Cancer Genomics and Proteomics*, 2010, 7(2), 67-73
91. Lane J, Martin TA, and **Jiang WG**. Targeting Rho-C by way of ribozyme transgene in human breast cancer cells and its impact on cancer invasion. *World Journal of Oncology*, 2010, 1(1), 7-13
92. Lane J, Martin TA, McGuigan C, Mason MD, **Jiang WG**. The differential expression of hCNT1 and hENT1 could have an impact on breast cancer therapy. *Journal of Experimental Therapeutics and Oncology*, 2010, 8 (3), 203-210
93. Davies SR and **Jiang WG**. ALCAM, activated leukocyte cell adhesion molecule influence the aggressive nature of breast cancer cells, a potential connection to bone metastasis. *Anticancer Research*, 2010, 30, 1163-1168

94. Al-Sarakbi W, Reefy S, **Jiang WG**, Roberts T, Newbold RF, Mokbel K. Evidence of a tumour suppressor function for DLEC1 in human breast cancer. *Anticancer Research*, 2010, 30, 1079-1082
95. **Jiang WG**, Ablin RJ, Ye L, Kynaston, Mason MD. The prostate transglutaminase, TGase-4, coordinate with the HGFL/MSP-ROn system in stimulating the migration of prostate cancer cells. *International Journal of Oncology*, 2010, 37, 413-418
96. Bokobza SM, Ye L, Kynaston HG, **Jiang WG**. GDF-9 promotes prostate cancer cell growth by protecting them from apoptosis. *Journal of Cellular Physiology*, 2010 Nov; 225 (2) : 529-36
97. Ye L, Bokobza S, Li J, Muhammed M, Chen JF, Mansel RE, **Jiang WG**. Bone morphogenetic protein-10 (BMP-10) inhibits aggressiveness of breast cancer cells in vitro and correlates to poor prognosis in breast cancer. *Cancer Science*, 2010, 101 (10), 2137-2144
98. **Jiang WG**, Ye L, Patel G, Harding KG. Expression of WAVES, the WASP (Wiskott-Aldrich Syndrome Protein) family of Verprolin Homologous proteins, in human wound tissues determines the fate of wound healing. *Wound Repair and Regeneration* 2010 Oct 13. doi: 10.1111/j.1524-475X.2010.00630.x
99. Al-Reefy S, Osman H, **Jiang WG**, Mokbel K. Evidence for a pro-apoptotic function of RACK1 in human breast cancer. *Oncogene*, 2010, 29(41), 5651
100. Bokobza SM, Ye L, Kynaston HG, **Jiang WG**. GDF-9 promotes adhesive and motile capacity of prostate cancer cells by up-regulating FAK and Paxillin via Smad dependant pathway. *Oncology Reports*, 2010, 24 (6), 1653-1660
101. Sanders AJ, Ye L, Mason MD, **Jiang WG**. Over-expression of EPLIN (Epithelial protein lost in neoplasm) affects endothelial cell migration, adhesion and tubule formation: potential implications in angiogenesis. *Angiogenesis*, 2010, 13, 317-326
102. Martin TA, Mansel RE, **Jiang WG**. Loss of occludin leads to the progression of human breast cancer. *International Journal of Molecular Medicine*, 2010 Nov; 26 (5) : 723-34.
103. Yu H, Ye L, **Jiang WG**. Knockdown of Ehm2 inhibits aggressiveness of breast cancer cells through regulation of MMP-9 expression, and aberrant expression of Ehm2 correlates with breast cancer metastasis. *Molecular Cancer Research*, 2010, 8(11), 1501-1512
104. Patani N, Douglas-Jones, A, Manel RE, **Jiang WG**, Mokbel K. Tumour suppressor function of MDA-7/IL-24 in human breast cancer. *Cancer Cell International*, 2010, 10, 29
105. Patani N, **Jiang WG**, Newbold RF Mokbel K. Tumour suppressor function of of CHiP and LyLOX in human breast cancer. *Journal of Carcinogenesis*, 2010, 9, 9 (DOI 10:4103/1477-3163:72505)
106. Chen JF, Xie F, Zhasng LJ, **Jiang WG**. iASPP is over-expressed in human non-small cell lung cancer and regulates the proliferation of lung cancer cells through a p53 associated pathway . *BMC Cancer*, 2010, 10(1), 694

2009

107. Martin TA and **Jiang WG**. Loss of tight junction barrier function and its role in cancer metastasis. *Biochimica Biophysica Acta*, 2009, 1788, 872-891
108. Malik FA, Sanders AJ, **Jiang WG**. KAI-1/CD82, The molecule and clinical implication in cancer and cancer metastasis. *Histology and Histopathology*, 2009, 24(4), 519-530
109. **Jiang WG**, Ablin RJ, Kynaston HG, Mason MD. The Prostate Transglutaminase (TGase-4, TGaseP) regulates the interaction of prostate cancer and vascular endothelial cells, a potential role for the ROCK pathway. *Microvascular Research*, 2009, 77, 150-157
110. Malik FA, Sanders AJ, Douglas_Jones AJ, Mansel RE, **Jiang WG**. Transcriptional and translational modulation of kai1 expression in ductal carcinoma of the breast and the prognostic significance. *International Journal of Molecular Medicine*, 2009, 23(2), 273-278
111. Fernando H, Martin TA, Douglas-Jones A, Kynaston HG, Mansel RE, **Jiang WG**. WASP and WAVE proteins: vital regulators of cell motility and the role in cancer. *International Journal of Molecular Medicine*, 2009, 23 (2), 141-148
112. Ye L, Kynaston H, **Jiang WG**. Bone morphogenetic protein-10 (BMP-10) suppresses growth and aggressiveness of prostate cancer cells through a SMAD independent pathway. *Journal of Urology*, 2009, 181, 2749-2759
113. Chen J, Ye L, Zhang LJ, **Jiang WG**. The molecular impact of pigment epithelium derived factor, PEDF, on lung cancer cells and the clinical significance. *International Journal of Oncology*, 2009, 35, 159-166
114. Zhang N, Sanders AJ, Ye L, **Jiang WG**. Vascular Endothelial Growth Inhibitor (VEGI) in Human Cancer. *International Journal of Molecular Medicine*, 2009, 24, 3-8

115. Bokobza SM, Ye L, Kynaston H, Mansel RE, **Jiang WG**. Reduced expression of BMPR-IB correlates with poor prognosis and increased proliferation of breast cancer cells. *Cancer Genomics and Proteomics*, 2009, 6, 101-108
116. Parr C and **Jiang WG**. Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer. *European Journal of Cancer*, 2009 Jun;45(9):1673-83
117. Ye L and **Jiang WG**. Bone Morphogenetic Proteins In Cancer, Clinical And Therapeutic Considerations. *Oncology News*, 2009, 4(3), 75-77
118. Bokobza SM, Ye L, **Jiang WG**. When BMP signalling goes wrong: The intracellular and molecular mechanisms of BMP signalling in cancer. *Current Signal Transduction and Therapies*, 2009, 4(3), 174-195
119. Kang H, Escudero A, Douglas-Jones A, Mansel RE, **Jiang WG**. Transcript analyses of stromal cell derived factors (SDFs), SDF-2, SDF-4 and SDF-5 reveals a different pattern of expression and prognostic association in human breast cancer. *International Journal of Oncology*, 2009, 35, 205-211
120. Al Sarakbi W, Sasi W, **Jiang WG**, Roberts T, Newbold RF, Mokbel K.. The mRNA expression of SETD2 in human breast cancer: correlation with clinico-pathological parameters. *BMC Cancer*, 2009, 9, 290
121. Malik FA, Sanders AJ, Kayani MA, **Jiang WG**. Effect of expressional alteration of KAI1 on breast cancer cell growth, adhesion, migration and invasion. *Cancer Genomics and Proteomics*, 2009, 6(4), 205-213
122. Patani N, **Jiang WG**, Mansel RE, Newbold R, Mokbel K. SATB1, a 'master genome organizer' in mammary carcinogenesis. *Cancer Cell International.*, 2009, 9(1), 18
123. Chen JF, Zhao W, Zhang JZ, **Jiang WG**, Zhang LJ. Effects of pigment epithelial derived factor gene on growth of lung cancer cell and neovascularization: experiments with lung cancer cells and chick embryos. *National Medical Journal of China*, 2009, 89(7), 485-490
124. Li J, Ye L, Parr C, Douglas-Jones A, Mansel RE, **Jiang WG**. The aberrant expression of bone morphogenetic protein 12 (BMP-12) in human breast cancer and its potential prognostic value. *Gene Therapy and Molecular Biology*, 2009, 13, 186-193
125. Escudero-Esparza A, Martin TA, Leigh-Davies M, **Jiang WG**. PGF isoforms, PLGF-1 and PGF-2, in colorectal cancer and the prognostic significance. *Cancer Genomics and Proteomics*. 2009, 6(4), 239-246
126. Zhang N, Sanders AJ, Ye L, Kynaston HG, **Jiang WG**. Vascular endothelial growth inhibitor (VEGI), expression in human prostate cancer tissue and the impact on adhesion and migration of prostate cancer cells in vitro. *International Journal of Oncology*, 2010, 35 (6), 1473-1480
127. Ye L, Bokobza S, **Jiang WG**. Bone morphogenetic proteins in the development and progression of breast cancer, and therapeutic potential. *International Journal of Molecular Medicine*, 2009, 24 (5), 591-597

2008

128. Davies G, Martin TA, Mason MD, **Jiang WG**. The role of PLC-gamma in HGF induced cell motility in prostate cancer. *Urologic Oncology*, 2008, 26(4), 386-391
129. Ye L, Lewis-Russel J, Kynaston HG, **WG Jiang**. HGF regulates the expression of BMP-7 in prostate cancer. *Urologic Oncology*, 2008, 26 (2)190-197
130. Davies S, Watkins G, King J, Mokbel K, Dent C, **Jiang WG**. ALCAM expression in primary breast tumour predict the likelihood of bone metastasis. *Oncology Reports*, 2008, 19(2), 555-561
131. Salhab M, **Jiang WG**, Newbold RF, Mokbel K. The expression of gene transcripts of telomere-associated genes in human breast cancer: correlation with clinico-pathological parameters and clinical outcome. *Breast Cancer Research and Treatment*, 2008, 109, 35-46
132. Martin TA, Pereira G, Watkins G, Mansel RE, **Jiang WG**. WASP is a putative tumour suppressor in breast cancer cells, *in vitro and in vivo*, and is associated with clinical outcome in patients with breast cancer. *Clinical and Experimental Metastasis*, 2008; 25 (2) : 97-108
133. Fernando H, Watkins G, Kynaston H, Mansel RE, **Jiang WG**. WAVE expression in human breast cancer. *Oncology*, 2008, 73 (5-6), 376-383
134. King JA¹, Stevens T¹, Shevde L¹, Ofori-Acquah S¹, **Jiang WG**². Prognostic value of N-cadherin in breast cancer. *Southern Medical Journal*, 2008, 101 (5), 470-475
135. Martin TA and **Jiang WG**. The impact of paracellin-1 in human breast cancer. *Journal of Cellular Biochemistry*, 2008, 105, 41-52
136. Lane J, Martin TA, Mansel RE, **Jiang WG**. Rho associated kinase, Rock-1 and Rock-2 in human breast cancer. *International Journal of Oncology*, 2008, 33 (3), 585-593
137. Cunnick GH, **Jiang WG**, Douglas-Jones, Watkins G, Gomez K, Morgan JM, Subramanian A, Mokbel K, Mansel RE. Lymphangiogenesis and lymph node metastasis in breast cancer. *Molecular Cancer*, 2008, 7, 23

138. Davies SR, Watkins G, Douglas-Jones A, Mansel RE, **Jiang WG**. Bone Morphogenetic Proteins 1 to 7 in Human Breast cancer, expression pattern and clinical/prognostic relevance. *Journal of Experimental Therapeutics and Oncology*, 2008, 8 (Nov), 327-338
139. Patani N, **Jiang WG**, Mokbel K. Osteopontin C mRNA expression is associated with a poor clinical outcome in human breast cancer. *International Journal of Cancer*, 2008, 122 (11), 2646
140. Ye L, Kynaston H, **Jiang WG**. Bone morphogenetic protein-9 (BMP-9) induces apoptosis in prostate cancer cells through prostate apoptosis response-4 (PAR-4). *Molecular Cancer Research*, 2008, 6, 1594-1606
141. Sanders AJ, Parr C, Martin TA, Lane J, Mason MD, Jiang WG. Genetic upregulation of matriptase-2 reduces the aggressiveness of prostate cancer cells *in vitro* and *in vivo* and effects FAK and paxillin localisation. *Journal of Cellular Physiology* 2008, 216(3), 780-789
142. Chen JF, Ye L, Zhang LJ, **Jiang WG**. Placenta growth factor, PlGF, influences the motility of lung cancer cells, the role of rho associated kinase, ROCK1. *Journal of Cellular Biochemistry*, 2008 Sep 1;105(1):313-20
143. Fernando H, Sanders A, Kynaston H, **Jiang WG**. WAVE1 is associated with invasiveness and cell growth in prostate cancer. *Journal of Urology*, 2008, 180, 1515-1521
144. Worku D, Jouhra F, **Jiang WG**, Patani N, Newbold RF, Mokbel K. Evidence of a tumour suppressive function of E2F1 in human breast cancer. *AntiCancer Research*, 2008, 28: 2135-2139
145. Sun J, Watkins G, Moskaluk C, Blair A, Lee J, **Jiang WG**, Li R. Association of Reduced Expression of Cofactor of BRCA1 (COBRA1) with Metastatic and Recurrent Breast Cancer. *Journal of Cellular Biochemistry*, 2008, 103 (6), 1798-1807
146. Patani N, Jiang WG, Mokbel K. Osteopontin expression profiles predict pathological and clinical outcomes in breast cancer. *Anticancer Research* 2008, 28: 4105-4110
147. Malik FA, Ashraf S, Kayani MA, **Jiang WG**, Baloch IA, Sadiq R. Contribution of BRCA1 germline mutation in patients with sporadic breast cancer. *International Seminars of Surgical Oncology*, 2008, 5: 21
148. **Jiang WG**, Martin TA, Russell-Lewis J, Ye L, Douglas-Jones A, Mansel RE. Eplln-alpha Expression In Human Breast Cancer, The Impact On Cellular Migration And Clinical Outcome. *Molecular Cancer*, 2008, 7(1), 71
149. Goyal A, Martin TA, Mansel RE, **Jiang WG**. Real-time PCR analysis of expression of E-cadherin, alpha-Beta-, and gamma-catenin in human breast cancer for predicting clinical outcome. *World Journal of Surgical Oncology*, 2008, 6(1), 56
150. Clark DW, Mitra A, Fillmore RA, **Jiang WG**, Samant RS, Fodstad O, Shevde LA. NUPR1 interacts with p53. Transcriptionally regulates p21 and rescues breast epithelial cells from Doxorubicin-induced genotoxic stress. *Current Cancer Drug Targets*, 2008, 8(5), 421-430
151. Malik FA, Kayani MA, Iqbal H, Mir A, **Jiang WG**, Sadiq R. Characterization of coding region of metastasis suppressor genes kiss1 and kai-1 for germ line mutations in breast cancer patients. *Gene Therapy and Molecular Biology*, 2008, 12, 239-246
152. Lane J, Martin TA, Mansel RE, **Jiang WG**. The expression and prognostic value of the guanine nucleotide exchange factors (GEFs) Trio, Vav1 and TIAM-1 in human breast cancer. *International Seminars of Surgical Oncology*, 2008, 5, 23
153. Chen L, Aeschlimann DP, Evans B, Waddington RJ, **Jiang WG** and Wei XQ. IL-23 promotes osteoclast formation by up-regulation of RANK expression. *European Journal of Immunology*, 2008, 38, 2845-2854
154. Patani N, **Jiang WG**, Mokbel K. Prognostic Utility of Glycosyltransferase Expression in Breast Cancer. *Cancer Genomics and Proteomics*, 2008, 5, 333-340

2007

155. **Jiang WG**, Fodstad O and Mansel RE. Metastatic breast cancer. In 'Breast Cancer Metastasis', Editors RE Mansel and WG Jiang, Kluwer Academic Publishers, *Cancer Metastasis Research and Treatment*, 2007, 11: 1-6
156. Al-Rawi M, Mansel RE, **Jiang WG**. Lymphangiogenesis and lymphatic spread of breast cancer cells. In 'Breast Cancer Metastasis', Editors RE Mansel and WG Jiang, Kluwer Academic Publishers, *Cancer Metastasis Research and Treatment*, 2007, 11: 219-240
157. **Jiang WG**. Polyunsaturated fatty acids and prostate cancer metastasis. Invited contribution to 'Prostate cancer metastasis' Editors R Ablin and MD Mason Kluwer Academic publishers, New York, 2007, *Cancer Metastasis Research and Treatment*, 2007, 10: p59-82
158. Davies G and **Jiang WG**. Hepatocyte growth factor/scatter factor and prostate cancer metastasis. Invited contribution to 'Prostate cancer metastasis'. Editors R Ablin and MD Mason Kluwer Academic publishers, New York, 2007, *Cancer Metastasis Research and Treatment*, 2007, 10: p195-218

159. Davies G, Harrison G, **Jiang WG**, Mason MD. β -catenin and E-cadherin adhesion complex abnormalities in the metastasis of human prostate cancer. 'Prostate cancer metastasis' Editors R Ablin and MD Mason Kluwer Academic publishers, New York, 2007
160. **Jiang WG**. HGF and its receptor as potential therapeutic targets in cancer. *Current Oncology*, 2007 Apr;14(2):66-9
161. Ye L, Kynaston H, **Jiang WG**. BMPs and their receptors in bone metastasis of prostate cancer. *Histology and Histopathology*, 2007, 22 (10), 1129-1147
162. Conway K, G Harrison, P Price, K G Harding, **W G Jiang**. Expression of HGF, HGF receptor and the JHGF regulators in the acute and chronic wounds in the lower limb. *Wound Repair and Regeneration*. 2007, 15 (5), 683-692.
163. Parr C and **Jiang WG** . HGF, HGF activator and inhibitors in Metastatic breast cancer. In 'Breast Cancer Metastasis', Editors RE Mansel and WG Jiang, Kluwer Academic Publishers, *Cancer Metastasis Research and Treatment*, 2007, 11, 171-202
164. Zia MK, Mansel RE, **Jiang WG**. Expression of PTHrP and PTHrPR in human breast cancer. *International Journal of Cancer Research*, 2007, 3(2), 92-102
165. Parr C, Sanders AJ, Davies G, Martin TA, Lane J, Mason MD, Mansel RE and **Jiang WG**. Matriptase-2 Inhibits Breast Tumour Growth *in vivo*, Suppresses Breast Cancer Cell Invasion and Migration *in vitro*, and is Associated with Good Prognosis in Breast Cancer Patients. *Clinical Cancer Research*, 2007, 15;13(12):3568-76
166. Rmali KA, Puntis MCA, **Jiang WG**. Tumour associated angiogenesis in human colorectal cancer. *Colorectal Diseases*, 2007, 9(1), 3-14
167. Hanavadi S, Martin TA, Mansel RE, **Jiang WG**. BMP-15 expression and its role in human breast cancer. *Annals of Surgical Oncology*, 2007, 14 (7), 2159-2166
168. Tracey A. Martin¹, Tapas Das², Robert E. Mansel¹ & Wen G. Jiang¹. Enhanced tight junction function in human breast cancer cells by anti-oxidant, selenium and polyunsaturated lipid. *Journal of Cellular Biochemistry*, 2007, 101 (1), 155-166
169. Conway K, G Harrison, P Price, K G Harding, **W G Jiang**. Vascular Endothelial Growth Inhibitor represents an important target for therapeutic angiogenesis in the lower limb. *International Wound Journal*, 2007, 4 (1), 55-64
170. Ye L, Lewis-Russell J, Kynaston H, **Jiang WG**. Regulation of BMP receptor expression in human prostate cancer cells by hepatocyte growth factor. *International Journal of Oncology*, 2007, 30(2), 521-529
171. Salhab M, Singh-Ranger G, Mokbel R , Jouhra F, **Jiang WG**, Mokbel K. Cyclooxygenase-2 mRNA expression correlates with aromatase expression in human breast cancer. *Journal of Surgical Oncology*, 2007, 96(5), 605-611
172. Davies S, Watkins G, Mansel RE, **Jiang WG**. Expression pattern of WISPs and their clinical significance. *Annals of Surgical Oncology*, 2007, 14(6):1909-18
173. Barnes, F Warnberg, G Farnie, D White, **WG Jiang**, E Anderson and NJ Bundred. Cyclooxygenase-2 inhibition effects on tumour growth, cell cycling and lymphangiogenesis in a xenograft model of breast cancer. *British Journal of Cancer*, 2007 Feb 26;96(4):575-82
174. Rmali KA, Watkins G, Douglas-Jones A, Mansel RE, **Jiang WG**. Angiopoietins Lack of Prognostic Significance in Ductal Mammary Carcinoma. *International Seminars of Surgical Oncology*, 2007, 4:6
175. Ye L, Jonathan M. Lewis-Russell, Howard Kynaston and WG Jiang. Endogenous BMP-7 controls the motility of prostate cancer cells through regulation of BMP Antagonists. *Journal of Urology*, 2007, 178, 1086-1091
176. Ye L, Kynaston HG, **WG Jiang**. Bone metastasis in prostate cancer, the molecular and cellular mechanisms. *International Journal of Molecular Medicine*, 2007, 20, 103-111
177. Davies G, Ablin AJ, Mason MD, Jiang WG. Expression Of The Prostate Transglutaminase (TGase-4) In Prostate Cancer Cells And Its Impact On The Invasiveness Of Prostate Cancer. *J Experimental Therapeutics and Oncology*, 2007, 6(3):257-64
178. Alok Chhabra, Khaled A. Rmali, Gareth Watkins, Robert E. Mansel, **Wen G. Jiang**. Expression of Transcription factor CREB-1 in human breast cancer and its correlation with prognosis. *Oncology Reports*, 2007, 18(4), 953-956
179. Subramanian A, **Jiang WG**, Mokbel K. Evidence for a tumour suppressive function of IGF1- binding proteins in human breast cancer. *Anticancer Res*. 2007 Sep-Oct;27(5B):3513-8.
180. Zia MK, Rmali K, Watkins G, Mansel RE, **Jiang WG**. The VHL family and the aggressiveness of human breast cancer. *International Journal of Molecular Medicine*, 2007, 20(4), 605-611

181. Sanders AJ, Parr C, Mason MD and **Jiang WG**. Suppression of Hepatocyte Growth Factor Activator Inhibitor-1 (HAI-1) leads to a more aggressive phenotype of prostate cancer cells *in vitro*. *International Journal of Molecular Medicine*, 2007, 20(4), 613-619
182. L Mansfield, A Subramanian, H Devalia, W G Jiang, R F Newbold and K Mokbel. hTERT mRNA Expression Correlates with Membrane-type-1 Matrix Metalloproteinase and Vascular Endothelial Growth factor Expression in Human Breast Cancer: A Correlative Study Using RT-PCR. *Anticancer Research*, 2007, 27, 2265-2268

2006

183. Cai J, **Jiang WG**, Grant MB, Boulton ME. Role of placenta growth factor (PLGF) and placenta growth factor/vascular growth factor (PLF/VEGF) heterodimer in regulation of angiogenesis in retinal microvascular endothelial cells. *Journal of Biological Chemistry*, 2006 Feb 10;281(6):3604-13
184. Hiscox S, **Jiang WG**, Kathrin Obermeier, Denise Barrow, Robert I Nicholson. Tamoxifen-resistant breast cancer cells display altered β -catenin phosphorylation and reduced intercellular adhesion. *International Journal of Cancer*, 2006, 118(2):290-301
185. Conway K, Harding KG, **Jiang WG**. Hepatocyte growth factor and its receptor complex in human wound repair. *Wound Repair and Regeneration*, 2006, 14 (1), 2-10
186. Harrison GM, Davies G, Martin TA, Mason MD, **Jiang WG**. Differential expression of variant CD44 isoforms in invasive and non-invasive prostate cancer cells. *Oncology Reports*, 2006, 15(1), 199-206
187. Congiatu C, Brancale A, Mason MD, **Jiang WG**, McGuigan C. Novel potential anti-cancer naphthyl phosphoramidates of BVdU: separation of diastereoisomers and assignment of the absolute configuration of the phosphorus center. *J Med Chem*, 2006, 49, 452-455
188. Parr C, and **Jiang WG**. The hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulates breast cancer metastasis, suppress tumour stromal interactions and display strong therapeutic potential. *International Journal of Cancer*, 2006 Sep 1;119(5):1176-83
189. **Jiang WG**, Douglas-Jones A, Mansel RE. Aberrant Expression Of 5-Lipoxygenase-Activating Protein (5-LOXAP) confers prognostic and survival significance in patients with breast cancer. *Prostaglandins Leukotriene and Essential Fatty Acids*, 2006 Feb;74(2):125-34,
190. **Jiang WG**, Raz A, Douglas-Jones A, Mansel RE. Expression of Autocrine Motility Factor (AMF) and its receptor, AMFR, in human breast cancer. *Journal of Histochemistry and Cytochemistry*, 2006 Feb;54(2):231-41
191. Hanavadi S, Martin TA, Mansel RE, **Jiang WG**. Interleukin-11 and its receptor expression in human breast cancer. *Annals of Surgical Oncology*, 2006, 13(6):802-8
192. **Jiang WG**, Watkins G, Douglas-Jones A, Mansel RE. Reduction of 15-lipoxygenase (15-LOX)-1 and 15-LOX-2 in patients with breast cancer. *Prostaglandins Leukotriene and Essential Fatty Acids*, 2006, 74(4), 235-245
193. **Jiang WG**, Watkins G, Holgrem L, Mansel RE. Angiomotin and its analogues in angiogenesis and spread of human breast cancer. *BMC Cancer*, 2006 Jan 23;6(1):16
194. **Jiang WG**, Gaynor Davies¹, Tracey A Martin¹, Christian Parr¹, Gareth Watkins¹, Malcolm D Mason², and Robert E. Mansel. Expression Of Membrane Type-1 Matrix Metalloproteinase, MT1-MMP In Human Breast Cancer And The Its Impact On Invasiveness Of Breast Cancer Cells. *International Journal of Molecular Medicine*, 2006, 17(4), 583-590
195. Zhang LJ, Chen M, Ke Y, Mansel RE, **Jiang WG**. Expression of PEDF in human non-small cell lung cancer and its clinical significance. *International Journal of Molecular Medicine*, 2006, 17 (5), 937-944
196. Martin TA, Das T, Mansel RE & **Jiang WG**. Synergistic regulation of endothelial tight junctions by antioxidant (Se) and polyunsaturated lipid (GLA) via Claudin-5 modulation. *Journal of Cellular Biochemistry*, 2006, 98, 1308-1319
197. Davies G, Rmaili K, Mason MD, **Jiang WG**. Tumour endothelial marker-8 (TEM-8) in human breast cancer, the correlation with angiogenesis. *International Journal of Oncology*, 2006, 29 (5), 1311-1317
198. Rmaili K, Puntis MCA, **Jiang WG**. Expression of VEGF and their receptors in human colon cancer. *International Journal for Cancer Research*, 2006, 2(1), 31-41
199. Haynes M, Martin TA, Matthews P, **Jiang WG**. Expression of tight junctional molecular occluding and ZO-1/ZO-1 in human bladder cancer. *British Journal of Cancer*, 2006 in press.
200. Cai J, **Jiang WG**, Boulton ME. Vascular endothelial growth factor induced endothelial cell proliferation is regulated by interaction between KDR, SH-PTP1 and eNOS. *Microvascular Research*, 2006 Jan;71(1):20-31.
201. Parr C, How CG, Harrison GM, Mansel RE, **Jiang WG**. Expression of VEGI, vascular endothelial growth inhibitor in human breast cancer. *Angiogenesis*, 2006;9(2):73-81

202. Martin TA, Gomez KF, Watkins G, Mansel RE, **Jiang WG**. BCSG-1 (Synuclein-gamma) in human breast cancer. *Oncology Reports*, 2006, 16(1):207-12
203. Salhab M, Al Sarakbi W, M. Reed, **Jiang W**, Mokbel K. The role of aromatase and 17 beta HSD Type 1 mRNA expression in predicting the clinical outcome in human breast cancer. *Breast Cancer Research and Treatment* 2006, 99 (2), 155-162
204. Cai J, Parr C, **Jiang WG**, Boulton ME. Expression of Pigment epithelial derived factor (PEDF) in human breast cancer and the impact on angiogenesis. *Clinical Cancer Research*, 2006, 12 (11), 3510-3517
205. Chong YM, Colston K, WG Jiang , AK Sharma, K Mokbel. The Relationship Between Insulin-like Growth Factor-1 System and Oestrogen Metabolising Enzymes in Breast Cancer Tissue and its Adjacent Non-Cancerous Tissue. *Breast Cancer Research and Treatment*, 2006, 99(3), 275-288
206. Bazou D, Gavies, G, **Jiang WG**, Coakley T. Rapid molecular responses of epithelial and cancer prostate cell lines upon cell-cell contact initiation in an ultrasound trap. *Cell Adhesion and Communications*, 2006 Sep-Dec;13(5):279-94
207. **Jiang WG**, Gaynor Davies, Malcolm D Mason², Howard Kynaston³, Oystein Fodstad Does PGC1/PPAR-gamma play a role Com-1/p8 induced tumour growth in prostate cancer. *International Journal of Molecular Medicine*, 2006, 18,1199-1176
208. **Jiang WG**, Gaynor Davies, Tracey Martin, Malcolm D Mason², Howard Kynaston³, Oystein Fodstad. Com-1/p8 is a putative tumour suppressor in prostate cancer. *International Journal of Molecular Medicine*, 2006, Nov;18(5):981-6
209. Hiscox S, Jordan NJ, **Jiang WG**, Harper M, McClelland R, Smith C and Nicholson RI. Chronic exposure to fulvestrant promotes overexpression of the c-Met receptor in breast cancer cells: implications for tumour-stroma interactions. *Endocrine-Related Cancer*, 2006 Dec;13(4):1085-99,
210. Elkak A, Mokbel R, Wilson C, **Jiang WG**, Newbold RF, Mokbel F. hTERT mRNA expression is associated with a poor clinical outcome in human breast cancer. *Anticancer Research*, 2006, 26(6C), 4901-4904
211. W Al Sarakbi, M J Reed, Simon, **WG Jiang**, K Mokbel. The role of STS mRNA expression in predicting the clinical outcome in human breast cancer. *Anticancer Research*, 2006, 26(6C), 4985-4990
212. Andrew J Sanders, Christian Parr, Gaynor Davies, Tracy A Martin, Jane Lane, Malcolm D Mason and **Wen G Jiang**. Genetic Reduction of Matriptase-1 Expression is Associated with a Reduction in the Aggressive Phenotype of Prostate Cancer Cell , in vitro and in vivo. *Journal of Experimental Therapeutics and Oncology*, 2006, 6(1), 39-48

2005

213. **Jiang WG**, Parr C, Martin TA, Davies G, Matsumoto K, Nakamura T.. Hepatocyte growth factor, its receptor cMET and their therapeutic value in cancer treatment. *Critical Review in Oncology and Hematology*, 2005, 53 (1), 35-69
214. Lansky E, **Jiang WG**, Mo H, Bravo L, Froom P, Neeman I, Campbell MJ. Therapeutic synergy in pomegranate. *Investigative New Drugs*, 2005, 23 (1), 11-20
215. Al-Rawi MA, Watkins G, Mansel RE, **Jiang WG**. Interleukin-7 upregulates expression of VEGF-D in breast cancer cells and induces lymphangogenesis in vivo. *British Journal of Surgery*, 2005, 92(3), 305-310
216. Al-Rawi MA, Mansel RE, **Jiang WG**. Lymphangiogenesis, the molecular and cellular mechanisms. *European Journal of Surgical Oncology*, 2005, 31 (2), 117-121
217. Hayes M, Martin TA, Matthews P, **Jiang WG**. Tight junctions in human bladder cancer. *International Journal of Molecular Medicine*, 2005, 16(1):3-9
218. Kang H, Mansel RE, **Jiang WG**. The role of Stroma-derived factor 1 (SDF-1) in the migration and invasion of breast cancer cells. *International Journal of Oncology*, 2005, 26(5), 1429-1434
219. Martin TA, Goyal A, Mansel RE, Watkins G, **Jiang WG**. The transcription factor for the E-cadherin complex, Twist, Slug and Snail, in human breast cancer. *Annals of Surgical Oncology*, 2005, 12(6), 1-9
220. Al-Rawi MA, Mansel RE, **Jiang WG**. Lymphangiogenesis, clinical implications in cancer and cancer metastasis. *Histology and Histopathology*, 2005, 20, 382-398.
221. Rmaili K, Puntis MCA, **Jiang WG**. Prognostic value of tumour endothelial markers (TEM) in human colon cancer. *World Journal of Gastroenterology*, 2005, 11 (9), 1283-1286
222. Lansky EP, Harrison G, Froom P, and **Jiang WG**. Pomegranate (Pinica Granatum) pure chemicals synergistically inhibit human PC-3 prostate cancer cells invasion across Matrigel. *Investigative New Drugs*, 2005, 23, 121-122
223. Watkins G, Doulas-Jones A, Bryce R, Mansel RE, **Jiang WG**. Expression of osteonectin (SPARC) in human breast cancer. *Prostaglandins Leukotrienes and Essential Fatty Acids*, 2005, 72, 267-272

224. Watkins G, Martin TA, Bryce R, Mansel RE, **Jiang WG**. Gamma linolenic acid regulates the expression of SPARC in human cancer cells. *Prostaglandins Leukotrienes and Essential Fatty Acids*, 2005, 72, 273-278
225. Al-Rawi MA, Mansel RE, **Jiang WG**. Interleukin-7 is a lymphangiogenic factor and the molecular pathways. *International Journal of Oncology*, 2005, 27(3), 721-731
226. Kang W, Watkins G, Douglas-Jones A, Mansel RE, **Jiang WG**. The elevated level of CXCR4 expression is correlated with lymph node metastasis in human breast cancer. *The Breast*, 2005 Oct;14(5):360-7.
227. Kang H, Parr C, Mansel RE, **Jiang WG**. Stroma-derived factor 1 (SDF-1) and the invasiveness of breast cancer cells, the clinical implications. *Breast Cancer Research*, 2005, 7, R402-R410
228. Martin TA, Watkins G, **Jiang WG**. Clinical value of VE-cadherin in assessing angiogenesis in human breast cancer. *Histopathology*, 2005, 46, 422-430
229. McGuigan C, Thiery JC, Daverio F, **Jiang WG**, Davies G, Mason MD. Anticancer ProTides: Tuning the activity of BVDU phosphoramidate related to thymectacin. *Bioorganic and Medicinal Chemistry*, 2005, 13(9), 3219-3227
230. **Jiang WG**, Gareth Watkins¹, Anthony Douglas-Jones², Kefah Mokbel³, Robert E Mansel¹, Oystein Fodstad⁴. Expression of Com-1/p8 in human breast cancer, and its relevance to clinical outcome and ER status. *International Journal of Cancer*, 2005, 117(5):730-7
231. Hurle R, Davies G, Kynaston H, **Jiang WG**. Hepatocyte growth factor and its receptor complex in human prostate cancer. *Histology and Histopathology*, 2005,20 (4) 1339-1349
232. **Jiang WG**, Watkins G, Martin TA, Sampson J, Lee-Jones L, Kefah Mokbel, Mansel RE. The expression of TSC genes in human breast cancer. *European Journal of Cancer*, 2005, 41(11), 1628-1636
233. Leris ACA, **Jiang WG**, Mokbel K. WNT5a shows characteristics of tumour suppressor gene in breast cancer. *Anticancer Research*, 2005 Mar-Apr;25(2A):731-4
234. **Jiang WG**, Davies G, Oystein Fodstad O. Com-1/p8 in oestrogen regulated growth of breast cancer cells, the ER-beta connection. *Biochemical and Biophysical Research Communications*, 2005, 330, 253-262
235. Leris ACA, Roberts TR, **Jiang WG**, Newbold RF, Mokbel K. Evidence for a Tumour Suppressive Function of APRG1 in Breast Cancer. *Breast Cancer Research and Treatment*, 2005, 93 (2), 97-100
236. **Jiang WG**, Davies G, Martin TA, Parcc C, Watkins G, Mason MD, Mokbel K, and Mansel RE. Molecular targeting of matrilysin and its impact on tumour growth in vivo, the potential implications in breast cancer therapy. *Clinical Cancer Research*, 2005, 11 (16), 6012-6019
237. **Jiang WG**, Martin TA, Davies G, Parr C, Mansel RE and Mason MD. The potential lymphangiogenic effects of hepatocyte growth factor/scatter factor in vitro and in vivo *International Journal of Molecular Medicine* 2005, Oct;16(4):723-8.
238. Zhang LJ, Chen M, Ke Y, Mansel RE, **Jiang WG**. Down-regulation of PEDF in lung cancer cells impact on lung cancer induced angiogenesis in vitro. *Oncology Reports*, 2005, 14 (6) 1615-1620
239. Zhang LJ, Chen JF, Ke Y, Mansel RE and **Jiang WG**. Detection of PEDF mRNA in NSCLC using real time quantitative PCR. *Chinese Journal of Chest Disease and Tuberculosis*, 2006, 29(2), 129-131
240. Zhang LJ, Chen JF, Ke Y, Mansel RE and **Jiang WG**. Expression of placental growth factor and pigment epithelium-derived factor in non-small cell lung cancer and the prognostic significance thereof. *Chinease Medical Journal (Zhonghua Yi Xue Za Zhi)*. 2005 Dec;85(47):3328-31
241. Kang H, Mansel RE, **Jiang WG**. Expression of SDF-1 and its receptor is linked to the nodal metastasis in human breast cancer. *Journal of Surgical Clinics and Research*, 2005;12(5):483-487
242. Zhang LJ, Chen JF, Ke Y, Mansel RE and **Jiang WG**. Hammerhead ribozyme inhibits the expression of PEDF in A549 cells. *Chinease Journal of Medicine*, in press
243. Zhang LJ, Chen JF, Ke Y, Mansel RE and **Jiang WG**. Real-time detection of PEGF mRNA in NSCLC using real time polymerase chain reaction. *Chinese Journal of Laboratory Medicine*, 2006, 29(4), 317-319
244. Zhang LJ, Chen JF, Ke Y, Mansel RE and **Jiang WG**. Real-time detection of PIGF mRNA in NSCLC using real time polymerase chain reaction. *Chinese Journal of Lung Cancer*, 2006, 9(2), 171-181
245. Rmaili K, Puntis MCA and **Jiang WG**. Targeting human tumour endothelial marker, TEM-8, in human vascular endothelial cells, using hammerhead ribozyme transgenes, the impact on in vitro angiogenesis. *Biochemical and Biophysical Research Communications*, 2005, 334 (1), 231-238
246. Martin TA, Watkins G, **Jiang WG**. Expression of the Kiss-1 gene and product, in human breast cancer. *Clinical and Experimental Metastasis*, 2005, 22 (6), 503-511
247. Martin TA, Watkins G, **Jiang WG**. Expression of the Coxsackie-adenoviral receptor, CAR, in human breast cancer. *Clinical and Experimental Medicine*, 2005, 5 (5), 122-128
248. Zhang LJ, Chen M, Ke Y, Mansel RE, **Jiang WG**. Expression of Placenta Growth Factor (PIGF) in human non-small cell lung cancer and its clinical and prognostic significance. *World Journal of Surgical Oncology*, 2005, 3 (1)68 (<http://www.wjso.com/content/pdf/1477-7819-3-68.pdf>)

249. Watkins G, Doulas-Jones A, Mansel RE, **Jiang WG**. Expression of thromboxane synthase (TBXAS1) and thromboxane A2 receptor (TBXA2R) in human breast cancer and its association with long term prognosis. *International Seminars of Surgical Oncology*, 2005 Oct 26;2(1):23
250. Congiatu C, McGuigan C, **Jiang WG**, Davies G, Mason MD. Naphthyl phosphoramidate derivatives of BVdU as potential anticancer agents: design, synthesis and biological evaluation. *Nucleosides Nucleotides Nucleic Acids*. 2005;24(5-7):485-9.
251. Parr C, Cai J, Boulton M, Mansel RE, **Jiang WG**. Placenta growth factor is over-expressed and has prognostic value in human breast cancer. *European Journal of Cancer*, 2005 Dec;41(18):2819-27

2004

252. Parr C, Cunnick G, Mansel RE, and **Jiang WG**. Expression on HGF, its activator and inhibitors in human breast cancer. *Clinical Cancer Research*, 2004, 10, 202-211
253. Davies G, Mason MD, **Jiang WG**. Targeting HGF receptor, cMET, using hammerhead ribozyme transgenes in human prostate cancer. *Prostate*, 2004, 60 (4), 317-324
254. Davies G, Mason MD, Mansel RE, **Jiang WG**. Expression of tumour-endothelial markers in human breast cancer. *Clinical and Experimental Metastasis*. 2004, 21, 31-37.
255. Alrawi MA, Mansel RE, and **Jiang WG**. Interleukin-7 regulates the growth of breast cancer cells, via a Wortmannin sensitive pathway. *British Journal of Surgery*, 2004, 91 (1), 61-68
256. Al-Rawi M, Mansel RE, and **Jiang WG**. Expression of IL-7 and its signalling intermediates in human breast cancer. *European Journal of Cancer*, 2004, 40 (4), 494-502
257. **Jiang WG**, Watkins G, Douglas-Jones A, Mansel RE. Psoriasis (S100A7) is aberrantly expressed in human breast cancer and is related to clinical outcomes. *International Journal of Oncology*, 2004, 25 (1), 81-86
258. Rmali K, Al-Rawi MA, Parr C, Puntis MCA, and **Jiang WG**. Regulation of expression of TEM-8 and in vitro tubule forming by interleukin-1 in endothelial cells. *International Journal of Molecular Medicine*, 2004 Jul;14(1):75-80
259. Albercht M, Gommersall M, Patel A, Moore JB, **Jiang WG**, Mansel RE, Lansky EP, Neeman I, Geldof AA, Kumi-Diaka J, and Cambell MJ. Pomegranate extracts potently inhibit proliferation, suppress invasion and modulate gene expression in human prostate cancer cells. *Journal of Medicinal Food*, 2004, 7(3), 274-283
260. Martin TA, Mansel RE, **Jiang WG**. Hepatocyte growth factor disrupts tight junctions in human breast cancer cells. *Cell Biology International*, 2004, 28(5), 361-371
261. Watkins G, Mansel RE, **Jiang WG**. Reduction of nuclear peroxisome proliferator activated receptor gamma and its co-activator, PGC-1 in human breast cancer. *Oncology Reports*, 2004 Aug;12(2):483-488
262. King JAC, Ofori-Acquah AF, Stevens T, Al-Mehdi AB, Fodstad O, **Jiang WG**. Prognostic value of ALCAM in human breast cancer. *Breast Cancer Research*, 2004, R478-487
263. Rmaili K, Parr C, Watkins G, Puntis MCA, **Jiang WG**. Tumour endothelial marker-8 (TEM-8) in human colon cancer, the correlation with angiogenesis. *European Journal of Surgical Oncology*, 2004 Nov;30(9):948-953
264. Parr C and **Jiang WG**. The Notch receptors, Notch-1 and Notch-2, in human breast cancers. *International Journal of Molecular Medicine*, 2004 Nov;14(5): 779-786.
265. **Jiang WG**, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K, Mansel RE. Differential expression of the CCN family members Cyr61 from CTGF and Nov in human breast cancer. *Endocrine Related Cancers*, 2004, 11: 781-791
266. Martin TA, Watkins G, Cunnick GH, Mansel RE, **Jiang WG**. Reduced expression of tight junction molecules, ZO-1, ZO-2 and ZO-3, in breast cancer is associated with poor outcome. *European Journal of Cancer*, 2004; 40(18):2717-2725

2003

267. Ye L, Martin TA, Mansel RE, **Jiang WG**. Biphasic effects of 17- β -oestradiol on expression of occludin and transendothelial resistance (TER) and paracellular permeability in human vascular endothelial cells. *Journal of Cellular Physiology*, 2003, 196, 362-369
268. **Jiang WG**, Douglas-Jones A, and Mansel RE. Level of expression of PPAR-gamma and its co-activator (PPAR-GCA) in human breast cancer. *International Journal of Cancer*, 2003, 106, 752-757
269. **Jiang WG**, Douglas-Jones A, Mansel RE. Level of expression of lipoxxygenase-5, 12, and 15 and cyclooxygenase in human breast cancer. *Prostaglandins Leukotrienes and Essential Fatty Acids*, 2003, 69 (4), 275-281
270. Martin TA, Parr C, Davies G, Matsumot K, Nakamura T, Mansel RE, **Jiang WG**. NK4 reduced HGF/SF and fibroblast induced breast tumour growth. *Carcinogenesis*. 2003, 24 (8), 1317-1325

271. Parr C and **Jiang WG**. Quantitative analysis of lymphangiogenesis in human colon cancer. *International Journal of Oncology*, 2003, 23, 533-539
272. **Jiang WG**, Grimshaw D, Lane J, Martin TA, Parr C, Davies G, Laterra J, and Mansel RE. Retroviral hammerhead transgenes to cMET and HGF/SF inhibited growth of breast tumour, induced by fibroblasts. *Clinical Cancer Research*, 2003, 9, 4274-4281
273. Martin TA, **Jiang WG**, and Harding KG. Effect of human fibroblast derived dermis on human tissue expansion. *Tissue Repair and Regeneration*, 2003, 11, 292-296
274. Al-Rawi M, Mansel RE, **Jiang WG**. Interleukin-7 (IL-7) and IL-7 signalling complex in human solid tumours. *Histology and Histopathology*, 2003, 18, 911-923
275. Martin TA, Harrison G, Mansel RE, **Jiang WG**. CD44 and ezrin complex in cancer metastasis. *Critical Reviews of Oncology/Hematology*, 2003, 46, 165-186
276. Davies G, Parr C, Davies G, Martin, TA, Lane J, Matsumoto K, Nakamura T, Mason MD, **Jiang WG**. NK4, an HGF/SF antagonist, inhibit HGF/SF and HGF/SF-producing fibroblasts induced prostate cancer growth in vivo. *International Journal of Cancer*, 2003, 106, 348-354
277. Lane J, Mansel RE, **Jiang WG**. Delta-6-desaturase and FAD3 expression in human breast cancer. *International Journal of Molecular Medicine*, 2003, 12, 253-257
278. **Jiang WG**, Ablin R, Douglas-Jones A, Mansel RE. Expression of transglutaminases and the clinical significance in human breast cancer. *Oncology Reports*, 2003, 10, 2039-2044
279. Cai J, Ahmad S, **Jiang WG**, Huang J, Kontos CD, Boulton M, Admad A. Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells. *Diabetes*, 2003, 52 (12), 2959-2968
280. Rmali K, Puntis MCA, **Jiang WG**. Expression of VEGF, VEGFRs and tumour endothelial markers in human colon cancer. *International Journal of Surgical Sciences*, 2003, accepted for publication
281. **Jiang WG**, Watkins G, Lane J, Douglas-Jones A, Cunnick GH, Mokbel M, Mansel RE. Prognostic value of Rho family and rho-GDIs in breast cancer. *Clinical Cancer Research*, 2003, 9 (17), 6432-6440

2002

282. Mason MD, Davies GD, **Jiang WG**. Cell adhesion and adhesion abnormalities in prostate cancer. *Critical Reviews in Oncology and Hematology*. 2002, 41, 11-28
283. Kim ND, Kaplan B, Gupta M, Amichay A, Lansky E, Livney T, Neeman I, Poirier D, Luu-The V, Nicholls P, Kirby A, **Jiang WG**, Mansel R, Mehta R, Gewirtz D. Chemopreventive and adjuvant therapeutic potential of pomegranate (*Punica granatum*) for human breast cancer. *Breast Cancer Research and Treatment*, 2002, 71, 203-217
284. Cunnick G, **Jiang WG**, Gomez KF, Mansel RE. Lymphangiogenesis in the metastasis of breast cancer. *Histology and Histopathology*, 2002, 17, 863-870.
285. **Jiang WG**, Martin TA, and Mansel RE. Molecular detection of micro-metastasis in breast cancer. *Critical Reviews in Oncology/Hematology*, 2002, 43 (1), 13-31
286. Gomez KF, Lane J, Cunnick G, Grimshaw D, **Jiang WG**, Mansel RE. From PCR to RCA: a surgical trainee's guide to the techniques of genetic amplification. *European Journal of Surgical Oncology*, 2002, 28, 554-556
287. Harrison G, G Davies, Martin TA, **Jiang WG**, and Mason MD. Distribution and expression of CD44 isoforms and ezrin during prostate cancer-endothelium interaction. *International Journal of Oncology*, 2002, 21, 935-940
288. **Jiang WG**. Quantitative analysis of lymphangiogenic markers in endothelial cells and breast cancer. *INSIGHT news*, 2002, 14, 14-15
289. Gomez KF, Lane J, Cunnick G, Grimshaw D, **Jiang WG**, Mansel RE. Genetic amplification and quantitation: their role in the detection of micrometastasis in breast cancer. *Surgical Oncology*, 2002, accepted for publication.
290. Cunnick GH and **Jiang WG**. Quantitation of lymphangiogenesis using the iCycler iQ™ real-time PCR detection system and Scorpions detection system. *BioRad Radiations*, 2002, 109, 34-36
291. Martin TA, Mansel RE, and **Jiang WG**. Antagonistic effect of NK4 on HGF/SF induced changes in the transendothelial resistance (TER) and paracellular permeability of human vascular endothelial cells. *Journal of Cellular Physiology*, 2002, 192 (3), 268-275

2001

292. **Jiang WG**, Grimshaw D, Leterra J, Abounader R, Lane J, Mansel RE. Suppression of invasiveness and cellular motility of breast cancer cells by a hammerhead ribozyme encoding cMET antisense. *Clinical Cancer Research*, 2001, 7, 2555-2562

293. Martin TA, Mansel RE, **Jiang WG**. HGF/SF modulation of the expression of VE-cadherin in human vascular endothelial cells. *Clinical Cancer Research*, 2001, 7, 734-737
294. Parr C, Davies G, Nakamura T, Matsumoto K, Mason MD, **Jiang WG**. A HGF/SF antagonist, NK4, regulates matrix-adhesion and paxillin phosphorylation in prostate cancer cells. *Biochemical and Biophysical Research Communications*, 2001, 285, 1330-1337
295. Parr C and **Jiang WG**. Hepatocyte growth factor/scatter factor, its activators, inhibitors and antagonists. *Histology and Histopathology*, 2001, 16, 251-268
296. Stephens P, Hiscox S, Cook H, **Jiang WG**, Wu Z, Thomas D. Phenotypic variation in the production of bio-active Hepatocyte Growth Factor/Scatter Factor by oral mucosal and skin fibroblasts. *Wound Repair and Regeneration*, 2001 9 (1), 34-43
297. Cunnick G, **Jiang WG**, Gomez KF, Mansel RE. Quantitation of lymphangiogenesis using real time quantitative PCR and breast cancer as a model. *Biochemical and Biophysical Research Communicationis*, 2001, 288, 1143-1146
298. **Jiang WG**. Gamma-linolenate and treatment of cancer, a new lead in cancer therapies. *Journal of Evidence-Based Oncology*, 2001, 3, 1-2
299. Davies G, Mason MD, Mansel RE, **Jiang WG**. Regulation of cell adhesion complexes by growth factors and the impact on cancer metastasis. In **Growth factors and their receptors in cancer metastasis** (ISBN 0-7923-7141-0), by **Jiang WG**, Matsumoto K, and Nakamura T (Editors), Kluwer Academic publishers, New York, 2001, pp 277-290
300. Davies G, **Jiang WG**, and Mason MD. HGF/SF modifies the interaction between cMET and E-cadherin/catenin complex in prostate cancer. *International Journal of Molecular Medicine*, 2001, 7, 385-388
301. Davies G, **Jiang WG**, and Mason MD. Interactin between β -catenin, GSK3 β and APC and its role in signal transductin pathways in prostate cancer. *International Journal of Oncology*, 2001, 18, 843-847
302. **Jiang WG** and Mansel RE. E-cadherin adhesion complex and its abnormalities in breast cancer. *Surgical Oncology*, 2001,9 (4), 151-171
303. Davies G, **Jiang WG**, Mason MD. The role of cell-cell adhesion molecules in prostate cancer progress. *Cancer Research Wales Annual Report*, 2001
304. Martin TA and **Jiang WG**. Tight junction and their role in cancer metastasis. *Histology and Histopathology*, 2001, 16, 1183-1195
305. Parr C and **Jiang WG**. Expression of HGF/SF, its activator and inhibitors in human cancer cells. *International Journal of Oncology*, 2001, 19(4), 857-863
306. Davies G, **Jiang WG**, Mason MD. The influence of HGF/SF on its receptor cMET, cell –cell adhesion complexes and the association of β -catenin with molecules involved in signal transduction pathways in prostate cancer progression. *Cancer Research Wales Annual Report*, 2001
307. Martin TA, Harding KG, **Jiang WG**. Matrix bound fibroblasts regulates angiogenesis by modulation of VE-cadherin. *European Journal of Clinical Investigation*, 2001, 39(11), 931-938
308. Davies G, **Jiang WG**, Mason MD. Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in HGF/SF induced cell-cell dissociation and in vitro invasion. *Clinical Cancer Research* 2001, 7, 3289-3297

2000

309. Hiscox S, Parr C, Matsumot K, Nakamura T, Mansel RE , **Jiang WG**. NK4, a HGF/SF variant, inhibits in vitro invasiveness of breast cancer cells. *Breast Cancer Research and Treatment*, 2000, 59, 245-254
310. **Jiang WG** and Mansel RE. Metastatic cascade. *Cancer Metastasis, Molecular and Cellular Biology and Clinical Intervention*. Edited by WG Jiang and RE Mansel. Kluwer Academic Publishers, 2000, pp 1-19
311. Davies G, **Jiang WG**, Mason MD. Cell-cell adhesion and signalling intermediates in human prostate cancer. *Journal of Urology*, 2000, 163, 985-992
312. **Jiang WG**, Martin TA, Llaflaffian L, Mansel RE. Tight Junction, a crtical structure in the control of cancer invasion and metastasis. In ‘Cancer Metastasis, Molecular and Cellular Basis and Clinical Intervention’, Editors **Jiang WG** and Mansel RE. Kluwer Academic Publishers, 2000, 195-214
313. Parr C, Hiscox S, Cai J, Matsumoto K, Nakamura T, **Jiang WG**. Inhibition of HGF/SF and fibroblasts induced motility and invasion of colorectal cancer cells by NK4, a new HGF antagonist. *International Journal of Cancer*, 2000, 85, 563-570
314. **Jiang WG**, Redfern A, Eynard AR, Mansel RE. Polyunsaturated fatty and the control of cancer invasion and metastasis. In ‘Cancer Metastasis, Molecular and Cellular Basis and Clinical Intervention’, Editors Jiang WG and Mansel RE. Kluwer Academic Publishers, 2000, 225-250

315. **Jiang WG**, RP Bryce, DF Horrobin, Mansel RE. Peroxisome proliferator activated receptor- γ mediates the effects of gamma linolenic acid in cancer cells. *Prostaglandins Leukotrienes Essential Fatty Acids*, 2000, 62(2), 119-127

1999

316. **Jiang WG** Hiscox S, Cai J, Martin T, Matsumoto K, Nakamura T, Mansel RE. Antagonistic effects of NK4, an novel HGF variant, on the in vitro angiogenesis of human vascular endothelial cells. *Clinical Cancer Research*, 1999, 5, 3695-3703
317. Hiscox S and **Jiang WG**. Ezrin regulates cell-cell and cell-matrix adhesion and serves as a tumour suppressor. *Journal of Cell Sciences*, 1999, 112, 3081-3090
318. **Jiang WG**, Hiscox S, Matsumoto K and Nakamura T. Hepatocyte growth factor/scatter factor/scatter factor, the molecular, cellular and clinical implications in cancer. *Critical Reviews in Oncology/Hematology*, 1999, 29, 209-248
319. **Jiang WG**, AE Eynard, RE Mansel. The pathology of essential fatty acid deficiency, a cell adhesion mediated phenomenon? *Medical Hypothesis*, 2000, 55 (3), 257-262
320. Davies EL, Gee JW, Cochrane RA, **Jiang WG**, Sharma AK, Nicholson RI, and Mansel RE. The immunohistochemical expression of desmoplakin in breast cancer compared with normal breast tissue and its role in invasion and metastasis. *European Journal of Cancer*, 1999, 35 (6), 902-907
321. **Jiang WG**, Martin TA, Nakamura T and Mansel RE. Hepatocyte growth factor/scatter decreases the expression of occludin and paracellular permeability and increases the transendothelial resistance of human vascular endothelial cells. *Journal of Cellular Physiology*, 1999, 181, 319-329
322. Davies G, **Jiang WG**, Mason MD. The role of cell adhesion molecules in the progression of human bladder and prostate cancer. Biennial Report of the Cancer Research Wales, 1999, 5 -11
323. Hiscox S and **Jiang WG**. Hepatocyte growth factor/scatter factor disrupts E-cadherin mediated cell-cell adhesion by induction of the phosphorylation of β -catenin. *Anticancer Research*, 1999, 19, 509-517
324. Hoppe A, Wertheim D, **Jiang WG**, Williams R, and Harding KG. A computer system for assessment of cancer cell movement. *Proceedings Medical Image Understanding and Analysis*, 1999, 121-124
325. **Jiang WG**. Angiogenesis, a SMR Symposium. *Current Drugs, Weekly highlights*. 1999
326. Cai J, **Jiang WG**, and Mansel RE. Gamma linolenic acid regulates angiogenic factor- and tumour-induced angiogenesis via its effect on the motility of endothelial cells. *Prostaglandins Leukotrienes and Essential Fatty Acids*. 1999, 60, 21-29
327. **Jiang WG**. Batimastat. *Current Opinions in Oncology, Endocrine and Metabolism*. 1999, 1 (5), 525-535
328. Davies G, **Jiang WG**, Mason MD. The role of E-cadherin and desmolein in motogen induced dissociation and invasion of human bladder cancer cells. *Anticancer Research*, 1999, 19, 547-552
329. Cai J, **Jiang WG**, and Mansel RE. Gamma linolenic acid inhibits expression of VE-cadherin and tube formation in human vascular endothelial cells. *Biochemical and Biophysical Research Communications*, 1999, 258, 113-118
330. Hoppe A, Wertheim D, **Jiang WG**, Williams R, Harding K. An interactive image processing system for assessment of cell movement. *Medical/Biological Engineering and Computing*, 1999, 37, 419-423
331. Cai J, **Jiang WG**, Mansel RE. Phosphorylation and disorganisation of vascular-endothelial-cadherin in the interaction between breast cancer and vascular endothelial cells. *International Journal of Molecular Medicine*, 1999, 4, 191-196
332. Martin TA, Harding KG, and **Jiang WG**. Regulation of angiogenesis and endothelial cell motility by matrix bound fibroblasts. *Angiogenesis*, 1999, 3, 69-76
333. Hiscox S and **Jiang WG**. Association of the HGF/SF receptor, c-MET, with the cell-surface adhesion molecule, E-cadherin and catenins in human tumour cells. *Biochemical Biophysical Research Communications*, 1999, 261, 406-411

1998

334. **Jiang WG**, Hiscox S, Horrobin DF, Bryce RP, Mansel RE. Regulation of nm23 expression by ω -6 polyunsaturated fatty acids. *British Journal of Cancer*, 1998, 77 (5), 731-738
335. **Jiang WG**, Hiscox S, Horrobin DF, Bryce RP, and Mansel RE. Essential fatty acids regulate the expression of tumour suppressor genes in cancer cells. *Essential Fatty acids and Eicosanoids*, Editor Professor Riemersma, American Organic Chemical Society (AOCS) Press, 1998, pp 303-311
336. Hoppe A, **Jiang WG**, Wertheim D, William R, Harding K. A system for computer analysis of cancer cell movement. *Anticancer Research*, 1998, 18, 2691-2694
337. Hiscox S and **Jiang WG**. Association of PTP μ with β -catenin in human cancer cells, a possible role for E-cadherin. *International Journal of Oncology*, 1998, 13: 1077-1080

338. **Jiang WG**, Bryce RP, Horrobin DF, and Mansel RE. Gamma linolenic acid blocks cell cycle progression by regulating the phosphorylation and interaction of p27 and p57 with other cell cycle regulators and cell cycle progression in cancer cells. *International Journal of Oncology*, 1998, 13, 611-617
339. Davies G, **Jiang WG**, Mason MD. E-cadherin and its associated molecules in the invasion and progression of prostate cancer. *Oncology Reports*, 1998, 5 (6): 1567-1676
340. Martin TA, Harding KG, **Jiang WG**. Regulation of cell motility and angiogenesis by Dermagraft, a role for CD44. *Proceedings of the European Wound Management Society*, Publisher, EMAP, 1998, in press
341. Eynard AR, **Jiang WG**, and Mansel RE. Eicosatrienoic acid (20:3, n-9) inhibits the expression of E-cadherin and desmoglein in squamous cell carcinoma. *Prostaglandins Leukotrienes and Essential Fatty Acids*. 1998, 59 (6), 371-377
342. Eynard AR, **Jiang WG**, and Mansel RE. Eicosatrienoic acid (20:3, n-9) regulate the expression of E-cadherin and desmoglein in squamous cell carcinoma. *Proceedings of the 17th International Cancer Congress*, Editors M Moraes, R Brentani and R Bevilacqua, Bologna (Italy), 1998, pages 233-238
343. **Jiang WG** and Harding. Enhancement of expansion of wound tissue and angiogenesis by matrix embedded fibroblasts (Dermagraft), a role for hepatocyte growth factor/scatter factor. *International Journal of Molecular Medicine*, 1998, 2 (2), 203-210
344. **Jiang WG**. Cell adhesion molecules in the development of cancer metastasis in the liver. *Journal of Hepato-Pancreato-Biliary Surgery*, 1998, 5(4), 375-382
345. Hoppe A, Wertheim D, **Jiang WG**, Williams R, Harding K. A computerized system for assessment of cancer cell movement. *Proceedings of the VIII Mediterranean Conference on Medical and Biological Engineering and Computing* (Lemosos, Cyprus, June 14-17, 1998), (ISBN 9963-607-13-6), page 1-4
346. Cai J, **Jiang WG**, and Mansel RE. The role of gap junction communications and tyrosine phosphorylation of connexin 43 in the interaction between breast cancer cells and vascular endothelial cells. *International Journal of Molecular Medicine*, 1998, 1 (1), 273-278
347. **Jiang WG**, Bryce RP and Horrobin DF. Essential fatty acids, the molecular and cellular mechanisms of their anticancer action and clinical implications. *Critical Reviews in Oncology/Haematology*, 1998, 27, 179-209
348. Martin TA, Harding KG, **Jiang WG**. Regulation of cell motility and angiogenesis by Dermagraft, a role for CD44. *Proceedings of the European Wound Management Society*, Publisher, EMAP, 1998
349. **Jiang WG**. Regulation of cell adhesion, a central mechanism in the anticancer action of essential fatty acids. *International Journal of Molecular Medicine*, 1998, 1: 621-626
350. **Jiang WG**, Bryce RP, Horrobin DF, and Mansel RE. Regulation of tight junction permeability and occludin expression by polyunsaturated fatty acids. *Biochemical and Biophysical Research Communications*, 1998, 244, 414-420

1997

351. Hiscox S, Puntis MCA, Nakamura T, Hallett MB, and **Jiang WG**. Expression of HGF/SF and its receptor cMET in human colon cancers. *Cancer Investigations*, 1997, 15(6), 513-521
352. **Jiang WG**, Hiscox S, Hallett MB, Bryce R, Horrobin DF, Mansel RE, and Puntis MCA. Inhibition of membrane ruffling and ezrin translocation by gamma linolenic acid. *International Journal of Oncology*, 1996, 9, 279-284
353. **Jiang WG** and Puntis MCA. Immune malfunction in patients with obstructive jaundice. *HPB Surgery*, 1997, 10, 129-142
354. **Jiang WG**, RP Bryce, DF Horrobin, Mansel RE. Gamma linolenic acid regulates gap junction communications in endothelial cells and their interaction with tumour cells. *Prostaglandins, Leukotrienes, and Essential Fatty Acids*, 1997, 56(4), 307-316.
355. Hiscox S and **Jiang WG**. Quantitation of tumour-endothelial interaction with DiI, 1,1'-dioctadecyl-3,3,3',3' tetramethylindocarbocyanine (DiI). *Cancer Letters*, 1997, 112, 209-217
356. **Jiang WG** and Hiscox S. Hepatocyte growth factor and c-met, a cytokine playing multiple and converse roles. *Histology and Histopathology*, 1997, 12, 537-555
357. Han ZG, Ma CJ, **Jiang WG**. Indicative role of membrane ruffling in the motility and invasion of cancer cells. *Journal of N.B. University of Medical Sciences*, 1997, 23 (6), 690-692 (R730.4)
358. Allman R, Cowburn P, **Jiang WG**, Mason M. Investigations of a cyclic peptide antagonist of the $\alpha\beta$ integrin: implications for targeted tumour therapy. Biennial Report of Cancer Research Wales, 1995-1996, 64-66
359. Hiscox S and **Jiang WG**. Expression of E-cadherin, alpha-, beta-, and gamma-catenins in human colorectal cancer. *Anticancer Research*, 1997, 17(2), 1349-1354
360. Hiscox S and **Jiang WG**. Interleukin-12, an emerging anti-tumour cytokine. *In vivo*, 1997, 11 (2), 125-132.

361. Davies EL, Cochrane RA, Hiscox S, **Jiang WG**, Sweetland HM, and Mansel RE. The role of desmoglein 2 and E-cadherin in the invasion and motility of human breast cancer cells. *International Journal of Oncology*, 1997, 11 (2). 415-419
362. **Jiang WG** and Hiscox S. β -catenin, cell adhesion and beyond. *International Journal of Oncology*, 1997, 11, 635-641
363. Hiscox S and **Jiang WG**. Regulation of expression of endothelial cell CD44 and endothelium-tumour cell interactions by hepatocyte growth factor/scatter factor. *Biochemical and Biophysical Research Communications*. 1997, 233, 1-5
364. **Jiang WG**, Singhrao SK, Hiscox S, Hallett MB, Bryce PB, Horrobin DF, Puntis MCA, and Mansel RE. Regulation of desmosomal cell adhesion in human tumour cells by polyunsaturated fatty acids. *Clinical and Experimental Metastasis*, 1997, 15(5), 593-602
365. Han ZG, Yan JD, **Jiang WG**. Effects of HGF on cellular motility and invasion of lung cancer cells. *Chinese Journal of Immunology*, 1997, 13, 280-282
366. **Jiang WG**, Hiscox S, Bryce RP, Horrobin DF, and Mansel RE. Gamma linolenic acid selectively regulates the expression maspin and motility of cancer cells. *Biochemical and Biophysical Research Communications*, 1997, 237: 639-644

1996

367. **Jiang WG**, Puntis MCA, Horrobin DF, Scott C, and Hallett MB. Inhibition of neutrophil respiratory burst and cytokine priming by gamma linolenic acid. *British Journal of Surgery*, 1996, 83, 659-664
368. **Jiang WG**. E-cadherin and its associated protein catenins, cancer invasion and metastasis. *British Journal of Surgery*, 1996, 83, 437-446
369. Puntis MCA and **Jiang WG**. Plasma cytokine levels and monocyte activation in patients with obstructive jaundice. *Journal of Gastroenterology and Hepatology*, 1996, 11 (1), 7-13
370. **Jiang WG** and Puntis MCA. Monocyte production of Interleukin-12 in patients with obstructive jaundice. *HPB Surgery*, 1996, 9, 219-221
371. **Jiang WG** and Hiscox S. Cytokine regulation of ezrin expression in the human colon cancer cell line HT29. *Anticancer Research*, 1996, 16(2), 861-867
372. Han ZG, **Jiang WG**, Hallett MB, Isoai A, Mansel RE. Inhibition of motility, dissociation, and invasion of human lung cancer cells by invasion inhibiting factor 2. *Surgical Oncology*, 1996, 5 (2), 77-84
373. **Jiang WG**, Hiscox S, Nakamura T, Hallett MB, Puntis MCA, and Mansel RE. Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (FAK) and paxillin and enhances cell-matrix interactions. *Oncology Reports*, 1996, 3, 819-823
374. **Jiang WG**. Biology of wound healing. Textbook for the Diploma of Wound Healing and Tissue Repair, WHRU, 1996, 4-41
375. Hiscox S and **Jiang WG**. Regulation of the expression of hepatocyte growth factor receptor, *c-met*, by cytokines. *Oncology Reports*, 1996, 3, 553-557
376. Han ZG, **Jiang WG**, Hiscox S, Nakamura T, Hallett MB, and Mansel RE. Regulation of motility, invasiveness, and growth of lung cancer cells by hepatocyte growth factor/scatter factor. *Surgical Research Communications*, 1996, 18, 217-229
377. Allman R, Cowburn P, **Jiang WG**, Mason M. Investigations of a cyclic peptide antagonist of the $\alpha v \beta 3$ integrin: implications for targeted tumour therapy. Biennial Report of Cancer Research Wales, 1996, 64-66
378. **Jiang WG**, Hiscox S, Puntis MCA, Hallett MB, Horrobin DF, Bryce R, and Mansel RE. Gamma linolenic acid (GLA) inhibits tyrosine phosphorylation of focal adhesion kinase (FAK) and paxillin and tumour cell-matrix interaction. *International Journal of Oncology*, 1996, 8, 583-587
379. **Jiang WG** and Mansel RE. Progress in anti-invasion and anti-metastasis research and treatment. *International Journal of Oncology*, 1996, 9(5), 1013-1028

1995

380. **Jiang WG**, Hiscox S, Hallett MB, Horrobin DF, Scott C, Puntis MCA. Inhibition of invasion and motility of human colon cancer cells by gamma linolenic acid. *British Journal of Cancer*, 1995, 71, 744-752
381. **Jiang WG**, Hiscox S, Hallett MB, Horrobin DF, Mansel RE, and Puntis MCA. Regulation of the expression of E-cadherin on human cancer cells by gamma linolenic acid. *Cancer Research*, 1995, 55 (Nov), 5043-5048
382. **Jiang WG**, Hiscox S, Singhrao SK, Puntis MCA, Nakamura T, Mansel RE, and Hallett MB. Induction of tyrosine phosphorylation and translocation of ezrin by hepatocyte growth factor (HGF/SF). *Biochemical and Biophysical Research Communications*, 1995, 217(3), 1062-1069

383. Hiscox S, Hallett MB, Puntis MCA, and **Jiang WG**. The role of E-cadherin in the motility, colony formation, and invasion of human colon cancer. *International Journal of Surgical Science*, 1995, 2, 177-182 (ISSN 1122-8687)
384. **Jiang WG**, Hiscox S, Horrobin DF, Hallett MB, Mansel RE, and Puntis MCA. Expression of catenins in human cancer cells and its regulation by n-6 polyunsaturated fatty acids. *Anticancer Research*, 1995, 15(6), 2569-2574
385. **Jiang WG**, Hiscox S, SK Singhrao, Hallett MB, Puntis MCA, Nakamura T, H Akedo, H Kumagai, and A Isoai. Inhibition of motility and invasion by invasion inhibiting factor 2 on human colon cancer cells. *Surgical Research Communications*, 1995, 17(1), 67-78
386. **Jiang WG**, Hiscox S, Hallett MB, Mansel RE, and Puntis MCA. Regulation of motility and invasion of cancer cells by human monocytes. *Anticancer Research*, 1995, 15, 1303-1310
387. **Jiang WG**. Membrane ruffling of cancer cells: A parameter of tumour cell motility and invasion. *European Journal of Surgical Oncology*, 1995, 21, 307-309
388. Hiscox S, Puntis MCA, Hallett MB, and **Jiang WG**. Inhibition of motility and invasion of human colon cancer cells by interleukin-12. *Clinical and Experimental Metastasis*, 1995, 13 (5), 396-404
389. **Jiang WG**, Hiscox S, SK Singhrao, Puntis MCA, Nakamura T, and Hallett MB. Inhibition of HGF/SF induced membrane ruffling and cell motility by transient elevation of cytosolic free calcium. *Experimental Cell Research*, 1995, 200, 424-433

1994

390. **Jiang WG**, Hallett MB, and Puntis MCA. Neutrophil priming by cytokines in patients with obstructive jaundice. *HPB Surgery*, 1994, 7, 281-289
391. Puntis MCA and **Jiang WG**. Effects of gamma linolenic acid and lithium linolate on human monocytes and hepatoma cells. in "New approaches to cancer treatment: Unsaturated lipids and photodynamic therapy" edited by Horrobin DF, by Churchill-Livingstone. 1994, pages 40-67
392. **Jiang WG**, Hallett MB, and Puntis MCA. Motility factors in cancer invasion and metastasis. *Surgical Research Communications*. 1994, 16, 219-237
393. **Jiang WG**. *In vitro* models of cancer invasion and metastasis: recent developments. *European Journal of Surgical Oncology*, 1994, 20 (4), 493-499
394. **Jiang WG**. Surgical training in China. Yearbook of Association of Surgeons in Training (1993-1994). Editor Rhodes M. by Stroudgate Plc, London 1994 page 170.
395. **Jiang WG**, Puntis MCA, and Hallett MB. The molecular and cellular basis of cancer invasion and metastasis and its implications for treatment. *British Journal of Surgery*. 1994, 81, 1576-1590

1993

396. **Jiang WG**, Puntis MCA, Hallett MB. Monocyte conditioned media possess a novel factor which increases motility of cancer cells. *International Journal of Cancer*, 1993, 53, 426-431
397. **Jiang WG**, Lloyd D, Puntis MCA, Nakamura T, Hallett MB. Regulation of spreading and growth of human colon cancer cells by hepatocyte growth factor. *Clinical and Experimental Metastasis*, 1993, 11(3), 235-242
398. **Jiang WG** and Puntis MCA. Monocyte secretion of hexosaminidase in patients with obstructive jaundice. *HPB Surgery*, 1993, Vol 7, 15-23
399. **Jiang WG**, Hallett MB, and Puntis MCA. Hepatocyte growth factor/scatter factor, liver regeneration and cancer metastases. *British Journal of Surgery*, 1993, 80(11), 1368-1373

1992

400. **Jiang WG**, Puntis MCA, and Hallett MB. U937 cells stimulated with opsonised zymozan provide a convenient source of tumour necrosis factor alpha. *Journal of Immunological Methods*, 1992, 152, 201-207
401. **Jiang WG**, Wang WZ, Li T. Interleukin-8, the biological and clinical implications (In Chinese). *Modern Medicine, Trauma and Surgery*, 1992, 3, 129-131
402. **Jiang WG**, Puntis MCA, Nakamura T, and Hallett MB. Neutrophil priming by hepatocyte growth factor, a novel cytokine. *Immunology* 1992, 77, 147-149

Before 1990

403. Wang B, Chen MH, Li JG, Dong B, Li L, Wang Z, Zhang Q, Liu Y, and **Jiang WG**. The diagnostic value of real time ultrasound in surgical emergency. *Chinese Journal of Surgery*, 1987, 25 (3), 146-148
404. **Jiang WG** and Wang WZ. The metastatic spleen tumours. *Modern Medicine*. 1989, 6, 62-69

Appendix-5 Publications: conference proceedings and abstracts - not listed